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The IVth International Symposium on Neural
Transplantation consisted of a total of 330 papers,
including 236 submitted papers. Of the submitted
papers, 27 were selected for oral presentation and
209 were chosen for poster presentation. In
addition, there were 94 invited oral presentations.
The total number of papers in the symposium series
continues to increase, from 215 papers presented in
Rochester in 1987 and the 233 papers presented in
Cambridge in 1989, representing a remarkable
continued increase in participation and expansion
of the field. The overall quality of the material
presented was outstanding, and there was a
substantial participation of scientists from various
fields related to neural transplantation, including
studies of neurotrophins and other growth factors,
CNS immunology, and brain development.
The following report represents a selective
discussion of papers which were presented at the
meeting. The amount of material presented was
vast, and no attempt has been made to be
comprehensive. Thus it should be emphasized that
many outstanding papers are not included in the
present report. Apologies are extended to the
numerous participants whose papers are not
described herein. Citations are given to the
abstracts (Restorative Neurology and
Neuroscience, Volume 4, number 3, July, 1992)
and extended abstracts (Journal of Neural
Transplantation and Plasticity, Volume 3, number
4, Oct. Dec., 1992), and to other primary sources
in some cases. Five abstracts of papers presented at
the symposium, which arrived too late for
publication, were printed in the meeting program.
This summary report covers selected aspects of
basic studies, CNS plasticity and development,
growth factors, immunology, cell lines, glial cells,
studies related to Parkinson’s disease and
catecholaminergic cells, Huntington’s disease,
cortical function, new models, and pain. Four
additional brief summary reports which discuss the
sessions on biomaterials and encapsulation, the
visual system, new animal models, and spinal cord
follow.
HUNTINGTON’S DISEASE
A session on Huntington’s disease included
papers on the properties and connectivity of striatal
tissue grafts in rodent models, as well as papers on
mechanisms through which striatal grafts produce
functional effects, behavioral models, and studies
in a primate model.
Graybiel and associates/52/described a well-
known excitotoxic model of Huntington’s disease
and its use for studies of transplantation.
Differentiation of striatal tissue was studied
following transplantation into the brain, using
immunocytochemical markers to characterize the
grafts. The striatal phenoytype was found to be
expressed, but only in parts or regions of the grafts.
Several striatal markers are expressed in patches of
striatal-like tissue, in a "matrix" er "surround" of
non-striatal tissue.
In normal striatum, c-los expressk,n (an early
marker of cell activation) in striatal cells is turned
on by cocaine, but only in those cells that express
the protein DARPP-32. Effects of cocaine on
DARPP-32-positive cells in striatal grafts were also
*This summary represents the impressions of the authors during the meeting. More precise and complete information can be
obtained from the abstracts (Restorative Neurology and Neuroscience, Volume 4, No. 3; July 1992) and the extended abstracts
(Journal of Neural Transplantation and Plasticity, Volume 3, No. 4; Oct-Dec 1992).
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examined: In grafted cells, cocaine also induced c-
fos expression only in DARPP-32-positive cells,
just as in the normal striatum. This suggests the use
of manipulation of c-fos expression with cocaine to
test for normal functioning of striatal tissue grafts.
Although these grafts develop similarly to normal
striatum, they are not identical. In particular, 6-
hydroxydopamine (6OHDA) causes increased
expression of enkephalin in the host brain, but
expression of enkephalin is hyper-increased in
grafts.
Wictorin and coworkers /153/ reported on
studies of the connectivity of striatal tissue grafts.
These grafts were found to have both efferent and
afferent connections with most of the brain regions
which normally project to the striatum. Afferent
connections include projections from cortex,
thalamus, doapminergic projections from host
substantia nigra (SN), and serotonergic projections
from host raphe nucleus. The major efferent
projection of striatal grafts appears to be to the
globus pallidus.
An important development in the potential use
of transplantation in Huntington’s disease is the
availability of a primate model. Isacson et al. /67/
described a baboon model of Huntington’s disease,
involving unilateral excitotoxic lesions of the
striatum induced by ibotenic acid or quinolinic
acid. Animals with these lesions do not show
spontanous abnormalities, but following
adminstration of apomorphine abnormal
movements, including chorea, orofacial
dyskinesias, and dystonia, are seen. Effects of
transplantation were examined in this model using
fetal rat donor tissue, in host animals
immunosuppressed with cyclosporin A. The
specificity of the grafts in inducing behavioral
recovery was illustrated by showing reversal of the
improvement after withdrawal of the
immunosuppression, and by implanting control
animals with brain stem tissue. This model will be
of considerable value in the future for development
of any procedure with potential applicability to
human patients.
Norman /100/ discussed and reviewed general
factors related to behavioral efficacy, and
techniques for intrastriatal implantation of grafts. It
was noted that striatal grafts can be behaviorally
effective when transplanted as solid tissue
fragments or as dissociated cells. Transplanted
astrocytes, however, produce considerably smaller
effects and by certain measures are not effective.
The grafts are effective only when placed into the
striatal parenchyma; striatal tissue grafts in the
lateral ventricle or the globus pallidus are not
effective. Some studies have also suggested that
striatal tissue grafts, and possibly grafts of other
cell types, may offer a partial protective effect
against subsequent excitotoxic lesions of the
striatum.
Most of the behavioral studies of striatal tissue
grafts have employed hyperactivity induced by
excitotoxic lesions of the striatum as a behavioral
measure. Striatal grafts reverse this hyperactivity
over the course of 3 9 weeks after transplantation,
and also can reverse amphetamine-induced
hyperactivity. More complex skilled behavioral
tasks which are impaired following excitotoxic
lesions of the striatum, such as paw reaching and
grasping of food pellets, are also improved
following striatal tissue grafts. Another model
which has been employed to assess the effects of
striatal tissue transplants is the use of rotational
behavior in response to apomorphine. One pitfall in
the use of this technique is that the rotational
behavior appears to vary with the specific lesion
location: More posterior lesions tend to produce
ipsilateral rotation, while more anterior lesions
produce more contralateral rotation. Sensitization
caused by repeated apomorphine injections must
also be taken into account when using rotational
behavior to assesss the effects of grafts. Also,
changes in the form of rotation can occur: Animals
may pivot in one spot, or they may walk around in
circles using all four paws. The pivotal form of
rotation is seen as being the more severe. Norman
/100/ suggested that striatal tissue grafts may
change the form of rotation from pivotal to walking
/also cf. 122/.
The final oral presentation on Huntington’s
disease models was given by Sirinathsinghi and
associates/129a,130/on the regulation of cellular
activity within striatal tissue grafts and in target
areas by afferent input. GABA release in the globus
pallidus was decreased 95% by striatal lesions;
striatal grafts restored pallidal GABA release to
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34% of normal levels. Both baseline GABA release
and amphetamine-stimulated GABA release were
similarly affected. Electron microscopic studies
have shown that tyrosine hydroxylase (TH)-
immunoreactive boutons synapse with dendrites
within the grafts, presumably indicating ingrowth
of dopaminergic axons. Expression of mRNA for
cholecystokinin, neuropeptide Y, dynorphin, and
pro-enkephalin in striatal grafts was generally
higher than in control striatum. Evidence was
presented suggesting that the dopaminergic
afferrentation of striatal grafts regulates mRNA
expression; this regulation was similar to normal
striatum in terms of both amount and direction of
the changes induced.
A particularly interesting finding was that GAP-
43 expression, a marker for elongating neurites,
was highly expressed in grafts for the first 30 days
after transplantation, and decreased to baseline
levels by 90 days after transplantation/130/. This
may indicate that synaptic growth and restructuring
within striatal tissue grafts is completed between 30
and 90 days after transplantation. This time course
resembles the time required for normal
development of striatal circuits. It was concluded
that there is very good growth of fibers into striatal
tissue grafts, even in mature host animals.
GROWTH FACTORS AND AXONAL GUIDANCE
Schwab and Schnell /125/ described studies
which shed light on the mechanisms which control
and limit CNS regeneration. Regeneration of
lesioned fibers involves sprouting, elongation, and
target recognition. Experiments by Aguayo and
others (e.g. /11/) in which peripheral nerve
segments were transplanted to bridge CNS lesions,
were described. Similar experiments were
conducted in vitro with sympathetic or sensory
neurons. Fibers grow into sciatic nerve but not into
optic nerve. Even if NGF is added to the medium in
large amounts, fibers do not grow into the optic
nerve, although general fiber growth is greatly
increased everywhere else. Thus, an inhibitory
factor must be present in optic nerve tissue.
This factor was found to be in the
oligodendrocyte membranes. Three molecules in
CNS myelin with molecular weights of 35, 60, and
250 kDa were implicated. Antibodies to each cross-
react, and the 35 kDa molecule is a subunit. The
active sites are found in the protein parts of the
molecule, not the carbohydrate. It is specific to
CNS myelin, and tightly bound to the membranes.
The protein is effective in very low concentrations,
equivalent to fractions of a ng per cm2 of dish. The
mode of action occurs through contact between
growth cones and CNS membranes. Following
such contact, the growth cones collapse. Antibodies
block the inhibitory effect on fiber growth, as well
as the inhibitory effect observed in growth cones.
Calcium in growth cones increases 30-fold
following contact with membranes, preceding the
growth cone arrest.
This information was employed to design in
vivo studies in the partially transected spinal cord.
The method used involved implantation of living
hybridoma cells, which produce a monoclonal
antibody to the inhibitory factor from oligo-
dendrocyte membranes. The hybridoma cells were
contained within a millipore filter matrix. Distances
to which sprouting fibers penetrated past the spinal
cord lesion were measured. In control animals,
these distances were rarely more than 1 ram, and
were usually in the range of 0.1 0.5 mm. With the
neutralizing antibody-producing cell implants, the
distances to which these fibers penetrated was
increased markedly, usually to 4 7 mm, and
sometimes as long as 11 mm. In one animal,
sprouting fibers penetrated 11 mm in 16 days.
What about the possibility of actually removing
oligodendrocytes? This can be accomplished by X-
irradiating the spinal cord at birth, as these are the
last cells to differentiate. In these irradiated
animals, distances of sprouting are also greatly
increased, usually to distances of between 4 and 8
mm, and sometimes more. These fibers can,
however, only grow through intact spinal cord, and
cannot cross a gap. Several materials were tried in
attempts to bridge the gap. None of these worked,
even though some of them work in the brain. Thus,
the spinal cord is an especially difficult tissue for
achieving CNS repair. Undoubtedly, future studies
will concentrate on the development of methods to
apply this strategy to repairing completely
transected spinal cord, such as closing the gap via
spondylectomy. Ultimately, this information will
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also be useful for studies of transplantation in
models of spinal cord injury (cf./109/).
The growing family of substances with
neurotrophic activity and their receptors, as well as
possible therapeutic applications, was the subject of
several papers /35,56,81,108,146/. The neuro-
trophins including nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT3) and neurotrophin-4 (NT4)
received particular emphasis. Oral session number
24 was devoted to papers on growth factors, with a
particular emphasis on studies aimed at stimulating
CNS plasticity. Ebendal /35/ described the use of a
mouse cell line, clone 3E, which contains several
hundred copies of the gene for rat NGF and
contains large amounts of NGF mRNA. These cells
,vere able to decrease the death of septal
cholinergic cells, from a loss of 27.5 to 8% of the
total cells, following implantation into a lesion
cavity in the fimbria-fornix. Another area of study
described by Ebendal /35/ involved the
development of spontaneously immortalized cells
from several fetal rat tissues, including muscle and
brain, which was achieved by long-term growth
and repetitive replating at low density. This is
similar to the methods which have previously been
used, for example, to develop the immortalized
NIH-3T3 mouse fibroblast cell line. Human NGF,
BDNF, NT3, and ciliary neurotrophic factor
(CNTF) constructs were expressed in immortalized
rat muscle cells. These cells were transplanted into
several brain areas, including the striatum and
hippocampus, using a total of 800,000 cells in two
4 tl injections. These cell grafts expand and
damage the host brain, thus removing some target
cells. Effects of the cell grafts on expression of
various mRNAs, such as those for the trk
neurotrophin receptors, the low-affinity NGF
receptor, and choline acetyltransferase, were
examined.
Persson /108/ described the target-derived
model for neurotrophins, according to which
neurotrophic molecules produced by target cells
play a role in the survival of neurons which provide
afferents to that system. The model described
involved the use of the whisker fields as target, and
trigeminal ganglion cells as afferents. When these
trigeminal neurons are cultured, NGF, NT3, and
NT4 promote survival very effectively, while
BDNF has a smaller effect. Areas of the brain
which were labelled for neurotrophins and their
receptors were also described. BDNF expression
was greatest in the substantia nigra, and NT-3
labelling was greatest in the spinal cord (also el.
/5/). The trk receptors, which confer the specificity
of neurotrophin interactions, also showed specific
regional distributions, with trk-B labelled most
strongly in the cortex and cranial nerve ganglia,
and trk-C most strongly labeled in cortex.
Carvey (/16/; also el. /17/) discussed the
distinction between target-derived factors with
trophic activity, autoconditioning factors, and
neuroinhibitory factors, as factors of each of these
different types may influence the developmtait and
function of dopaminergic neurons. The growth-
promoting activity of striatal extracts on primary
cultures of dopaminergic neurons was described.
Factors influencing this growth-promoting activity
were examined. It was found that activity was
decreased by kainic acid lesions of the striatum and
chronic administration of dopamine agonists, and
increased by chronic administration of dopamine
antagonists. Carvey /16/ also described a factor of
less than 10 kDa molecular weight which is a
neuroinhibitory factor for TH-positive
mesencephalic cells.
A detailed description of the known effects of
BDNF on dopaminergic and cholinergic neurons
was presented by Hefti /56/. For cholinergic
neurons, BDNF in a concentration of about 1 ng
per ml, is as effective as NGF. NGF, however, is
effective at approximately 100-fold lower
concentrations. In vivo, BNDF was evaluated for a
protective effect on septal cholinergic neurons
following knife-cut lesions of the fimbria-fornix.
Using this in vivo model, BDNF was considerably
less effective than NGF in preventing neuronal
death. There is also evidence that cholinergic
activity regulates BDNF expression.
In mesencephalic cell culture, BDNF produces
an approximately two-fold maximal increase in
dopamine uptake. The maximal stimulation of
dopamine uptake by basic fibroblast growth factor
(bFGF) is about 1.5-fold. Des-IGF1 also has a
slight effect. Interestingly, neither BDNF nor bFGF
increases total neurite length or the number of
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branching points. Mainly, BDNF increases only the
number of primary neurites. BDNF does not
increase TH expression, and it has a very modest
effect on neuron survival. BDNF does, however,
significantly protect against MPTP-induced
toxicity (also cf./7/). Thus, it does not appear that
BDNF fulfills all of the criteria which would be
expected for a dopamine neuron neurotrophic
factor. In an axonal transection model, which
induces a 70% loss of SN dopaminergic neurons,
BDNF was not effective in preventing cell death,
whether administered into the ventricle, lesion site,
or directly to the cell bodies. It is possible,
however, that BDNF works in concert with other
factors to regulate growth and differentiation, and
that no single substance regulates trophic effects on
dopaminergic neurons.
TRANSPLANTS FOR THE STUDY OF
DEVELOPMENT
Fekete and co-workers/36a/discussed the use
of gene transfer techniques to study cell lineage in
the developing brain. Three histochemical markers,
i-galactosidase, alkaline phosphatase, and an
antibody to the viral protein GAG, can be used to
identify marked cells. Viral vectors insert their
genes into dividing cells only when the cells are
dividing. Early in development, labelling a cell will
mark several cell types and a variety of clones,
while cell progenitors marked later in development
produce fewer clones. One technique that was
employed to increase the percentage of cells that
were labelled for transplantation was the use of
cells producing replication-competent virus, rather
than disabled virus, as is usually employed. Using
this technique, essentially all donor cells were
labelled. The problem of subsequent viral
replication was controlled through the use of hosts
which are resistant because they lack the receptors
for viral proteins which are required for infection.
Sotelo and Avarado-Mallart /134/ described
studies of expression of the protein Rat 401, using
immunohistochemical studies. This protein is a 200
kDa glial intermediate filament, not an adhesion
molecule. It is normally present in glial cells only
when subserving Purkinje cell migration. The
presence of immature transplanted Purkinje cells
induces expression of Rat 401, suggesting that
immature Purkinje cells interact with glia to induce
expression of Rat 401. Even though it is not an
adhesion molecule, adhesion events could very
well induce expression. Also, it was pointed out
that Rat 401 re-expression can be induced by other
methods in other brain regions.
O’Leary and Schlaggar /101/ considered
processes of cortical differentiation. Cortical areas
can be sharply distinguished by either
cytoarchitectonics or input-output projections. In
general, fetal cortical regions can assume the
attributes of other cortical regions when
transplanted. For example, barrel fields can
develop in foreign transplanted cortical regions. At
relatively later stages of cortical development,
clonally-related cells become widely distributed to
cortical areas.
An interesting study by Krum /77/ employed the
glial toxin 6-aminonicotinamide to examine the
role of glial factors in blood-brain barrier
development. Brain-derived endothelial cells
develop blood-brain barrier properties only if co-
cultured with astrocytes. Krum/77/administered 6-
aminonicotinamide to neonatal animals, giving four
systemic injections of 10 mg/kg during the first
weeks of life. This dosage causes damage of both
astrocytes and oligodendrocytes, and in the
experimental animals widespread spongy
degeneration in grey and white matter and swelling
of astroglial processes were seen. When
administered to adult animals, 6-aminonicotin-
amide caused glial degeneration only in specific
regions of spinal cord, medulla, cerebellum, and
thalamus. In neither neonatal nor adult animals
were the tight endothelial cell junctions damaged,
although there was evidence of protein leakage
through venous hemorrhages in the adult animals.
This method may nevertheless be of interest for
other purposes related to studies on the role of glia
in CNS development and plasticity; for example,
studies akin to those by Schwab (see section on
Growth and Trophic factors, above; /125/), who
showed that removal of oligodendrocytes by X-
irradiation promoted neurite growth in the injured
spinal cord.
Another interesting technique was described by
Macklis /88/, for producing a highly selective
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model of neuronal degeneration. Macklis and
Madison /89/ described the use of laser
illumination of brain tissue, using long wavelengths
(650 850 rim), which are abl to pnetrate brain to
a depth of several mm. A non-toxic dye, chlorin e6,
was incorporated into latex nanospheres, and these
nanospheres can in turn be incorporated into cells,
such as neuroblastoma cells. This compound, when
illuminated by sufficiently intense light in the near-
infrared range (660-670 nm), generates singlet
oxygen (102), which is toxic to cells. Chlorin e6
continues to generate singlet oxygen for extended
periods without bleaching. Normal tissue is thus
unaffected by the laser light, while grafted
neuroblastoma cells incorporating the chlorin e6-
latex nanospheres are destroyed by the laser
illumination/89/.
Macklis /88/ discussed the use of this method to
produce highly selective lesions of cortical
pyramidal cell populations, through retrograde
transport of such chromolytic dyes. When neuronal
populations which have accumulated these dyes are
illuminated by laser light, the neuronal population
is destroyed without damage to intermixed neurons,
glia, or blood vessels. Transplantation of fetal
cortical neurons into these areas of neuronal
depopulation revealed that: (i) the transplanted
neurons migrated for up to 1 mm and were
integrated specifically into the zones of neuronal
depopulation; (ii) control grafts of other types of
neurons into kainic acid-lesioned hosts showed
minimal spread of the transplanted neurons without
preference for the lesioned lamina II/III; (iii)
transplanted neurons within the lesioned zones
tended to assume a pyramidal shape, while
transplanted neurons found in other areas were not
pyramidal. This technique allows for investigation
of graft-host neuronal integration with minimal
interference from factors such as gliosis and crude
disruption of the brain parenchyma, as compared to
other models and more crude lesioning techniques.
Doucet and coworkers /27/ studied the ability of
neonatal (P7 and P14) and adult serotonergic
neurites to grow into transplanted fetal (El4)
mesencephalic tissue. They found that the fetal
mesencephalic grafts received a profuse
serotonergic afferentation when transplanted into
P7 hosts, but not when transplanted into P14 or
adult hosts. This study is of interest because even
adult serotonergic neurites are able to grow
profusely into other types of fetal CNS grafts.
Thus, there is a target tissue-specific loss of growth
potential of serotonergie fibers, which takes place
between postnatal days 7 and 14, and is specific for
the target tissue, rather than for the afferent system.
It was suggested that serotonergie axons bear
tissue-specific receptors which control their growth
with a different developmental sequence in
different brain regions.
ALZHEIMER’S DISEASEANDMEMORY MODELS
A number of interesting models were described,
in which grafts of acetyleholine-rieh tissues
(septum or basal forebrain), raphe neurons, or
hippocampus were transplanted into the
hippocampus of animals with hippoeampal injury
or deafferentation. Hedges et al. /62/ discussed
experiments involving hippoeampal or basal
forebrain tissue grafts in animals with hippoeampal
injury induced by ischemia, exeitotoxie lesions, or
colchicine. Nilsson et al./99/described studies of
acetylcholine release from septal grafts in the
hippocampus. Factors which influence recovery of
function following grafts of eholinergie neurons in
animals with septohippocampal injury were
discussed by Will and coworkers/155/.
Kolb /74/ presented studies involving lesions of
the medial prefrontal cortex. Such lesions induce
deficits in learning and memory, particularly on
tasks which involve a delay, and deficits in skilled
forepaw movements. Unilateral lesions produce no
lasting deficits, so that studies of these cortical
lesions require the use of bilateral lesions. The
effects showed a strong dependence on age.
The task selected was the Morris water maze, in
which animals are required to swim in a tank of
water (made opaque with milk) to find a
submerged platform. Animals with frontal cortical
lesions never learn to find the platform directly.
They always continue to find the submerged
platform using an indirect strategy, such as looping
or searching. Thus their performance may improve,
but they continue to show the qualitative deficit of
not being able to locate the platform directly.
Grafts of fetal cortex tended to improve
JOURNAL OFNEURALTRANSPLANTATION & PLASTICITYA REPORT ON THE IVTH INTERNATIONAL SYMPOSIUM 67
performance only when tested early after
transplantation. At later time intervals, grafts
resulted in poorer performance.
Dunnett and coworkers /31/ described studies of
cognitive function using a model involving
fimbria-fornix lesions, which disconnect the
hippocampal formation from its subcortical inputs.
Effects of intrahippocampal grafts of septal or
raphe neurons were used to study the possibilities
for functional restoration. Two operant behavioral
tasks (that is, tasks based on lever-pressing) were
described, delayed matching-to-sample and
"differential reinforcement of low rates" (DRL), a
form of timing behavior. Deficits in delayed
matching-to-sample recovered gradually, over the
course of 6 35 weeks. The DRL task was
ultimately more useful, as the deficits were long-
lasting and stable. This task involves imposition of
a 20 second delay, following which a lever-press
response is reinforced with a food pellet.
Responses which occur prior to the 20 second
delay interval are not reinforced and reset the 20
second clock. This forces the animals to time the
20 second interval accurately. The performance of
the animals can be evaluated in terms of percent
efficiency. Thus, if an animal responds 12 times
and receives 3 reinforcements, it has responded
with a 25% efficiency. This test is highly sensitive
to hippocampal damage.
THE BLOOD-BRAIN BARRIER
Study of the blood-brain barrier in
transplantation involves several issues, including
new vessel growth, astroglial participation and
immune responses. Pappas and Sagen /106/ have
described the use of opioid peptide-producing
chromaffin cells for pain reduction (see /119/).
When chromaffin cells are grafted, the endothelia
retain their fenestrated phenotype and are leaky to
protein. These investigators suggested, however,
that the vessels in such grafts also have the
important function of endocytosis and subsequent
elimination of immunologically active compounds
in the graft circulation that might cause graft
rejection. Therefore, the graft vasculature is
important for endogenous metabolic functions. The
paper by Krum /77/ emphasized the relationship of
astroglia and barrier competent vessels and has
been described previously under the section on
"Transplants for the study of development".
Broadwell and associates/13/provided a review of
the blood-brain barrier under normal conditions
and the different approaches to examining changes
at the light and electron microscopic level. The
authors displayed various permeations in the blood-
brain barrier and angiogenesis following a large
series of central and peripheral grafts. Their studies
of syngeneic, allogeneic or xenogeneic grafts
suggested that neither the barrier nor the purported
immunological privilege of the CNS is absolute.
Finsen and colleagues/37/described the expression
of immunological markers on activated astroglial
cells following xenografting and other non-graft
models of brain injury, such as chemical lesioning.
Rejection following xenogeneic grafting caused
infiltration of reactive cell types. MHC antigens
Class I and Class II were induced on microglia, and
Class I only on some astrocytes. Injury in the
hippocampus following ischemia or kainate
lesioning caused widespread induction of Class I
on microglial cells. Brightman and Ishihara /12/
used skeletal muscle autografts to examine the
phenomenon of neurovascular specificity. The
muscle grafts, when placed within the ventricle,
were vascularized by vessels that resemble those
normally found in muscle. Interestingly, in
bilaterally ganglionectomized hosts, choroidal
vessels which were fenestrated, unlike vessels in
muscle, entered into the muscle grafts. The authors
suggested that there may be an autonomic
determinant of vessel type. The muscle autografts
were also used to examine the entry of
intravascularly injected dye-labeled macrophages
through the muscle and into the brain parenchyma.
IMMUNOLOGY
Papers presented on immunology included
studies on immune mechanisms/59,138/as well as
papers on the relative susceptibility of grafts to
rejection /6,68,79,111,132/ depending on various
techniques, including transplantation methods and
genetic factors.
The opening paper was given by Streilein/138/,
who described studies of the mechanisms ot
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induction of immune unresponsiveness induced by
the implantation of various immunogenic materials,
such as tissue grafts, into the anterior chamber of
the eye. This phenomenon is termed "anterior
chamber-associated immune deviation" (ACAID).
Data suggesting a possible role of TGF-13 in
ACAID were presented. Studies of transplantation
of neonatal retinas into both the subconjunctival
space (a non-privileged site) and the anterior
chamber were described. Grafts in the
subconjuntival space were rejected readily. Grafts
into the anterior eye chamber also did not survive
permanently; however, they displayed a range of
survival times depending on genetic disparity"
Allografts with major MHC disparity survived for
17 35 days, while allografts with only minor
MHC disparity survived for more than 70 days.
Even isografts did not survive permanently. The
rejection was unusual, in that inflammation was not
seen, even for the allografts. It was suggested that
the deterioration of the isografts was caused by
transplantation-induced sensitization to retinal
antigens.
Sloan and coworkers /132/ presented data on the
induction of sensitization to brain tissue allografts
by a second graft of donor tissue into the kidney
capsule. Removing the second graft five days after
it was implanted did not cause an interruption in
the reaction to the CNS graft. Thus, CNS immune
reactions can be self-sustaining once initiated. It
was also noted that there was better survival and
less reaction to brain tissue grafts in the brain
parenchyma, as compared to grafts in the third or
lateral ventricle.
Poltorak and associates/68,111/found that even
when the host animals are systemically sensitized,
there are certain strain combinations that resist
brain graft rejection. Whereas rejection of grafts
from Brown Norway donors was readily induced in
all host strains, grafts from Lewis or Fisher 344
donors (both RT1) survived even after systemic
sensitization in many host strains. Conversely, for
some strain combinations, including one that did
not reject grafts after sensitization (Lewis donors to
AO-RTI hosts), there was evidence of graft
damage even without systemic sensitization. It was
also noted that expression of MHC Class I and II
antigens did not predict graft rejection, as grafts
located in the third ventricle frequently showed
strong expression of MHC antigens but were not
rejected. It was also noted that cellular infiltration
into brain grafts results in rejection only when the
infiltrating cells include T-helper and T-cytotoxic
lymphocytes, as well as perivascular infiltration.
Cell infiltration may also consist of mieroglia
expressing MHC Class II antigens, and this latter
form of cell infiltration does not result in graft
rejection.
Hickey /59/ (also el. /60/), in the concluding
paper, described a series of experiments on the
mechanisms through which T-cells are able to enter
into the CNS. The model used involved the use of
T-cells derived from Lewis rats, which could be
recognized by an antibody specific to the Lewis
RT-IX MHC molecule. The T-cells were activated
by various treatments, and then injected into either
Dark Agouti (RT-1) hosts, which do not produce
the RT-la molecule, or Lewis hosts. When non-
stimulated lymphocytes depleted of lymphoblasts
were injected, virtually none were found in the
brain following injection. Activation of the
lymphocytes using the mitogenic lectin
concanavalin A, to induce the cells to enter a
lymphoblast phase, allowed the cells to enter the
CNS freely, regardless of antigenic specificity of
the cells. The peak concentrations of cells in the
brain were found between 3 and 12 hours after
injection. It had previously been shown that anti-
myelin basic protein T-cells produce EAE only if
stimulated prior to injection into animals (e.g.
/105/). These data may help to explain the fact that
rejection of brain grafts can be induced by systemic
sensitization, even though T-cells cannot normally
gain access to the CNS. Apparently, the reaction of
T-cells with the CNS requires activation of the
cells in addition to the appropriate antigenic
specificity.
A population of T-cells derived from a normal,
unstimulated animal will contain a proportion of
blast cells. A continuous low level of entry of these
lymphoblast cells, with various antigenic
specificities, was suggested to continuously
"survey" the CNS. After CNS allografts, Hickey
/59/ demonstrated the presence of rare donor-
specific T-cells in the spleen and lymph nodes of
the host. Hickey /59/suggested that the fact that
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these cells are rare, and that even fewer would be in
blast phase at any one time, would result in an
inability of T-cells with appropriate specificities to
"find" the graft. In other words, even though CNS
allografts induce a small degree of host
sensitization, the level of sensitization is not
sufficient to result in graft rejection unless the
animal is systemically sensitized or receives a
second graft.
The question naturally arises whether allografts
can be rejected in non-immunosuppressed hosts,
and what circumstances might lead to graft
rejection. The ability of brain allografts to survive
is ultimately an empirical question; there are
several studies which suggest that brain allografts
usually survive, but can be rejected in certain host-
donor combinations, at least in some
circumstances. Hickey’s hypothesis /59/ suggests
that rejection of brain allografts might potentially
be provoked by two factors: either (i) a specific
stimulation of the host, resulting in an expansion of
the population of donor-specific T-lymphocytes, or
(ii) non-specific host stimulation, resulting in a
greater proportion of cells in the lymphoblast
phase, or some combination of the two. In fact, the
relative role of the two factors in sensitization-
induced brain allograft rejection has not been
systemically studied, as systemic sensitization
generally induces both a specific sensitization in
addition to a non-specific T-cell activation.
Studies of graft rejection and tolerance have
been almost entirely focused on the role of surface
antigens, and especially histocompatibility complex
antigens. Lampson /79/ reported findings which
suggest that, at least under come conditions, even
internal antigens may play a role in graft rejection.
The enzyme 13-glactosidase (3-gal), derived from
E. Coli, is often used as a cellular marker for
studies of genetic alteration of cells. Cells can be
made to express this enzyme constitutively by
retroviral transfer of the (5-gal cDNA. In
Lampson’s experiments /78/, the 9L gliosarcoma
cell line, derived from F344 rats and altered to
express 13-gal, was transplanted into F344 hosts.
F344 animals were systemically immunized with
purified I-gal prior to transplantation of 13-gal-
positive 9L cells into the brain. It was found that
prior immunization with 5-gal significantly
reduced the growth of the transplanted [3-gal-
positive 9L cells. It was pointed out that T-cells
recognize antigen in combination with MHC
antigens, rather than free antigen. The complex of
MHC with the target antigen might be formed
either within the transplanted target cell, or by an
antigen-presenting cell after ingestion of the target
antigen, culminating in rejection indirectly through
a "bystander" type response. Thus, it is possible
that non-MHC antigens may provoke graft
rejection, even when there is no MHC disparity.
Finally, an observation reported by Ibarra et al.
/65/ was that acute spinal cord injury markedly
reduced the absorption of the immunosuppressant
drug cyclosporin A. After oral administration of
cyclosporin A, serum levels were markedly
reduced in animals with acute spinal cord injury,
whereas blood levels of cyclosporin A were
increased after intraperitoneal administration.
Absorption was normal for both oral and
intraperitoneal administration in animals with
chronic spinal cord injury. These differences were
attributed to delayed gastric emptying (oral
administration) and vascular dilatation (intra-
peritoneal administration). Altered drug absorption
after spinal cord injury would have to be taken
account of in any studies of spinal cord injury
which require drug administration.
CELL IMPLANTS: USE OF SUPPORT MATRICES
AND ENCAPSULATION
One theme expressed in several contexts
throughout the meeting was the possibility of the
use of support systems for the implantation of cell
lines into the CNS. The topic of biomaterials and
encapsulation is discussed in an accompanying
summary by Sanberg and coworkers /121/. One
type of support system involves the use of semi-
permeable capsules in which cells are contained
and are implanted into the brain. The pore size of
the capsules is sufficiently small (approximately 50
kDa) to exclude cells and presumably to exclude
large protein molecules and antibodies, thereby
providing an immunoprotective effect. Small
molecules, such as neurotransmitters and growth
factors, can freely diffuse out of the capsules.
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New findings regarding transplantation of
encapsulated cells included a report on the possible
use of pancreatic -cell lines for GABA-releasing
encapsulted grafts/144/. There have been several
suggested potential applications for GABA-
releasing neural implants, including Huntington’s
disease, epilepsy, and Parkinson’s disease.
Pancreatic 13-cells are known to express glutamic
acid decarboxylase, the GABA synthetic enzyme.
Two immortalized cell lines derived from rat and
mouse IS-cells, designated NIT-1 and RIN, were
found to release GABA. In vitro, both cell lines
were found to survive encapsulation and continued
to release GABA. Preliminary data on intracerebral
implantation of these encapsulated cells were also
reported. If methods for the intracerebral
transplantation of cells capable of releasing large
amounts of GABA could be developed, it might
lead to a number of new applications for
intracerebral transplantation.
New data on encapsulated PC12 cell grafts in
animal models of Parkinson’s disease were also
reported /1,36,157-159/. Emerich and coworkers
/36/described a series of preclinical experiments
on the development of encapsulated PC12 cells as a
potential treatment for Parkinson’s disease,
including studies on encapsulation techniques,
asssessment of biocompatibility and
immunoprotection, and functional efficacy. Winn
and coworkers /157/ reported that encapsulated
PC12 cell grafts could be retrieved from the host
brain intact, with the encapsulated cells remaining
viable, and producing minimal damage to the host
brain. Winn and coworkers /158/ also compared
tissue reactions following capsule implantation.
Stereotaxic implantation either directly or using a
teflon cannula resulted in minimal tissue reaction,
whereas biocompatibility was poor when the
capsules were inserted using a glass cannula or
when sterility was compromised.
A second category of cell support systems seeks
to use polymers or protein matrices to support cell
attachment without encapsulation. Such systems
serve to localize and stabilize cell populations, but
do not provide immunoprotection or containment.
Where simple diffusion of products from cell to
host brain targets is not sufficient to produce a
functional effect, enclosed capsules cannot be used.
This would be the case where any form of physical
interaction between graft and host is required,
including invasion of cells, ingrowth of processes,
or extension of neurites from grafted cells into the
host brain.
Such cell matrices may allow for physical
contact between implanted cells and host brain,
possibly resulting in synapse formation and cell-
cell interactions which require membrane to
membrane cell contact. Several of these cell
support systems were described and used in
experimental transplantation systems. These
included implantation of hybridoma cells in a
Millipore filter matrix/125/, and studies by Silver
in which differences between immature and mature
glial cells in terms of their ability to become
incorporated into implanted Millipore filters were
described/95/. Another support system, employed
by Ebendal et al. /35/, involved the use of a
collagen gel as a matrix for the implantation of
NGF-producing cells into lesion cavities in the
fimbria-fornix. Woerly /160/ described the use of
collagen and methacrylate matrix co-polymers, and
described several structural formulations which
might be used for transplantation, either by
injection of cells into the matrices or by entrapment
of cells by rehydration of the polymers in the
presence of a cell suspension.
GLIAL CELLS
Silver /95/ described differences betwen the
glial reactions which are observed when
nitrocellulose Millipore filters are implanted into
the brains of immature or mature rats. In general,
when these filters are implanted into the brains of
immature rats, cells, consisting of microglia and
"flat" cells, invade the filters, followed by axons
and blood vessels. When these filters are implanted
into the brains of mature rats, the implant is instead
walled off by a gliotic scar. In host animals 8-14
days of age and older, there is a greater glial
fibrillary acid protein (GFAP)-positive glial
reaction around the implant, and a much smaller
migration of cells into the implant. Thus, the glial
reaction tends to wall off the implant from the rest
of the brain, rather than incorporating the implant
into the brain structure. Also, in older hosts, a
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patterned formation of blood vessels, as indicated
by laminin staining within the implant, does not
take place, the blood vessels are leaky, and laminin
is irregularly deposited.
The filters can also be explanted and used as a
substrate for cultured neurons. In all cases they
support neuronal survival, but there is a substantial
difference between the explants from the younger
vs. the older host animals in terms of the degree to
which they support neurite extension; the implants
from the younger animals are several times more
effective in supporting the extension of neurites.
This difference appears to be related to the
expression of proteoglycans, which inhibit neurite
growth via a repulsive (non-permissive), but non-
toxic, mechanism. These molecules are associated
with boundaries between neuronal structures,
similar to what has been found for tenascin.
The role of glial maturity in this phenomenon
was investigated by incorporating young or old
astrocytes into the filters, and then transplanting the
glia-containing filters into the brain. When filters
containing mature glia were transplanted, a GFAP-
immunoreactive scar formed in the surrounding
medium, and there was blood-brain barrier leakage
and poor blood vessel formation. When immature
glia were implanted with the filters, the GFAP-
positive scar in the surrounding medium did not
form, and there was normal formation of blood
vessels with much less leakage of the blood-brain
barrier. It was also noted that the cells did not
migrate out of the implants.
Similar phenomena are observed even if
conditioned media from mature vs. immature
astrocyte cultures are used to impregnate the filters,
rather than the cells themselves. When the filters
are impregnated with conditioned medium from
immature astrocytes plus mature astrocytes, the
regrowth is inhibited and resembles that which is
seen with mature astrocytes alone. This again
confirms that these phenomena are caused by an
inhibitory property of mature astrocytes, rather than
a stimulatory property of immature astrocytes/95/.
Geller /92/ described experiments on the effects
of bFGF on extracellular matrix expression in
astrocyte cultures, bFGF was found to increase
tenascin expression and decrease expression of
laminin, bFGF treatment of astrocyte cultures
reduced neuronal adhesion. Following neuronal
injury, it may be that the action of growth factors
plays a role in inhibiting recovery and synaptic
restructuring. In some cases, this type of
extracellular environment may inhibit graft
integration into the host brain. Simply transplanting
cells into the brain in such a neurite-inhibiting
environment may not be sufficient to result in
functionally significant restructuring. Several
papers, in fact, discussed aspects of the effects of
the local glial environment or microenvironment on
graft-host connectivity /18,24,44/. For example,
Castro et al. /18/found that there were substantial
differences in connectivity between cortical grafts
and host brain, when the grafts were placed into
excitotoxic cortical lesions, as compared to
aspiration cavities. Dellman and Carithers/24,25/
found that neurosecretory axon regeneration
required living glial cells; cryotreated neural lobe
or sciatic nerve grafts did not support
neurosecretory axon regeneration, as compared to
intact neural lobe and intact sciatic nerve.
A related study was presented by Nieto-
Sampedro and coworkers/98/, who employed the
technique of coating tissue culture dishes with
plasma membranes isolated from normal or gliotic
brain tissue. Membranes from the gliotic tissue
were found to inhibit neurite extension. The
inhibitory activivy was found to be present in a
proteoglycan, which was sensitive to digestion with
glycosaminoglycan lyase. A core protein with 48
kDa molecular weight was found to undergo a
large increase in injured brain tissue and was able
to inhibit neurite extension, and to induce neurite
retraction when added to cultures in soluble form.
This factor was distinct from neurite inhibitors
contained in myelin, and was localized to
microglial membranes by immunostaining.
GENETIC ENGINEERING
Several topics related to genetic engineering
were presented in sessions throughout the meeting.
For example, Glorioso /49/ presented a detailed
summary of the obstacles to the use of viral vectors
derived from Herpes Simplex viruses (HSV) for
insertion of genes into CNS cells, as well as
information on possible solutions. These viruses
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have a tendency to establish lifelong infections in
neurons, in a latent state without lytic infection.
The major difficulties related to this approach
include the development of mutant viruses which
do not destroy brain tissue, and the development of
a means to induce expression of the transferred
gene during latency. Directions for the
development of solutions to these problems were
explored. For example, control of the ability of
these viruses to damage brain tissue might involve
the use of certain mutants, such as a deletion
mutant which blocks viral replication in neurons
but not in culture. Certain latency-associated
transcripts are expressed while the virus is in a
latent state. Natural promoters in the latency-
associated transcript region of the gene might be
employed to drive foreign gene expression. Further
development of these possibilities may result in
HSV-derived viruses which can be reliably
employed to stably transfer genes into neurons in
situ. Data on the expression of tyrosine
hydroxylase through the use of an HSV-derived
vector was presented by During and coworkers
/32/. These authors showed data on TH
immunoreactivity in cells around the site of viral
injection into the brain, and data on behavioral
changes in animals receiving these injections.
An important factor in the development of
applications for transplantation of genetically-
engineered cells is the development of a means to
control gene expression. Studies reported by
LaGamma and colleagues/78/have begun to look
at this possibility. The strategy used was to employ
inducible promoters, in conjunction with the gene
for chloramphenicol acetyl transferase, in primary
cultures of rat striatal astrocytes. Expression of the
chloramphenicol acetyl transferase gene product
was measured by immunocytochemistry and by a
biochemical assay. One promoter used was the
human preproenkephalin promoter, which is known
to be regulated by the cAMP-dependent second
messenger system. Dopamine can. regulate cAMP
production in astrocytes, and was found to induce
increases in chloramphenicol acetyl transferase
expression, which were mimicked by dopamine
agonists and blocked by dopamine antagonists.
When transplanted into the brain, chloramphenicol
acetyl transferase expression was increased 2-fold
by amphetamine. Grafts placed into the striatum of
animals with unilateral dopamine depletion showed
30% less activity as compared to grafts in the intact
striatum. Further development of the possibility of
graft regulation may greatly facilitate both
experimental studies and ultimately application to
human disease.
There were several reports on the development
of immortalized cells /21,66,104,113,141/, most
often using retroviral transfer of oncogenes such as
the temperature-sensitive form of the SV40 large T
antigen (tsA58). This general approach was
reviewed by McKay /21/, who discussed the
process of cell differentiation in the CNS and
described the origin of neurons and glia. The HiB5
cell line, derived from fetal rat hippocampus using
tsA58, was found to differentiate, forming cells
with both neuronal and glial properties when
implanted into the neonatal rat hippocampus or
cerebellum (cf./113/). Another cell line, described
by Takashima and coworkers /141/, was derived
from El4 mesencephalon also using tsA58, and
showed increased expression of neurofilament
immunoreactivity in response to growth in brain-
conditioned medium. This cell line stopped
growing when confluent, even at the permissive
temperature. Another cell line, derived from rat
Schwann cells using the 12S E1A gene, was found
to produce insulin-like growth factor-1 (IGF-1) and
NGF receptor /66/. These cells did not show
growth in soft agar, and did not produce metastases
when implanted subcutaneously into animals. On
the other hand, these cells grew in a hyperplastic
manner, essentially forming localized tumors.
These ceils were not able to infect co-cultured
NIH-3T3 fibroblasts, but ultrastructurally showed
occasional viral budding.
Another interesting technology, which will
almost certainly be employed more widely in the
future as an experimental model, is the use of
transgenic animals as a source of cells for
transplantation. Aramant and Seiler /2/ employed
this technique as a method for labelling and
identifying donor cells following transplantation to
the retina. Transgenic NSE-lacZ mice contain the
13-galactosidase gene coupled to the promoter for
neuron-specific enolase /38/. Thus, when
transplanted cells express neuron-specific enolase,
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the 13-galactosidase gene will also be expressed and
can be used as a marker. In the retina of this mouse
strain, 13-galactosidase is expressed in the ganglion
cell layer, part of the inner nuclear layer, and the
inner and outer plexiform layers. When used for
transplantation to the retina, labelled cells could be
identified using this method. It was pointed out
that, since not all donor cells express 13-
galactosidase, not all transplanted cells could be
identified using this method, although a fraction of
the transplanted cells could be identified clearly.
Kershaw et al. /72/ employed tsA58 transgenic
mice/71/as a source of tissue for transplantation,
and found that the grafts developed normally,
without forming tumors. Other related techniques,
involving derivation of cells from transgenic
animals, are likely to be applied in transplantation
models in the future.
NGF, CO-GRAFTS, CHOLINERGIC SYSTEMS, AND
ADRENALMEDULLA TRANSPLANTATION
Studies of adrenal medulla transplantation,
methods for delivery ofNGF to the brain, co-grafts
of peripheral nerve segments, and other effects of
trophic factors have become so interlinked that it is
impossible to discuss these issues separately. Thus,
studies of delivery of NGF into the brain by
genetically-altered cells have potential applications
for use in cholinergic systems, and related methods
may also be used for delivery of other trophic
factors (see section on trophic factors, above).
However, several studies of NGF delivery
presented at the meeting were directed at enhancing
the survival of adrenal medulla grafts, and the
entire topic of NGF delivery into the brain, along
with related methods, will be discussed in the
context of adrenal medulla transplantation.
Adrenal medulla grafts:
Unisicker et al. /146/discussed growth factors
found in adrenal chromaffin cells. Growth factors
and cytokines which are found in adrenal
chromaffin cells include interleukin (IL)-2, IL-6,
insulin-like growth factor (IGF)-I, IGF-2,
transforming growth factor (TGF)-31, TGFI32,
TGFI33, bFGF, aFGF, and a CNTF-like molecule.
The contents of chromaffin cell granules include, in
addition to catecholamines, ATP, chromogranin,
and peptides. Release of catecholamines and
chromogranin can be induced using carbachol.
Unisicker described the use of a chromaffin cell-
conditioned medium assay to measure the
promotion of survival of neurons. Carbachol-
induced release of catecholamines was found to be
parallelled by a release of trophic activity.
Verapamil blocked all three (catecholamines,
chromogranin, and trophic activity release)
similarly.
bFGF is found in chromaffin cells; it is
localized to the granules, not the cytosol. This is
surprising, because bFGF lacks the signal peptide
needed for release. Although bFGF gets out of the
cells, the mechanism of release is not known.
Unisicker has not been able to show stimulated
release of bFGF. It was found that whole
chromaffin cells contain two bFGF-immuoreactive
molecules, with molecular weights of 32 and 46
kDa; granules contain the 46 kDa form almost
exclusively, bFGF is 18 kDa. This 46 kDa
molecule is biologically simlar to bFGF, but seems
to be a different molecule. Adrenal medullectomy
causes death of preganglionic spinal cord neurons
which innervate the adrenal medulla. Growth
factors which can prevent this cell death and are
present in the adrenal medulla include bFGF, as
well as TGF53, TGF2, and the CNTF-like
molecule.
Chromogranin A is present in the adrenal
medulla in large amounts. It was affinity purified
using a monoclonal antibody. Purified chromo-
granin A was found to have trophic activity for
dorsal root ganglia neurons. Surprisingly, this
trophic activity was increased seven-fold by
boiling. Additional increases in trophic activity
were obtained by further purification; the trophic
activity was highest in a 28 32 kDa molecular
weight band. After purification, its efficacy was
similar to that of NGF. This activity was not
blocked by several monoclonal antibodies,
including NGF antibodies. However, chromogranin
A produced by 3T3 tranfected cells did not have
trophic activity. Possibly there is some additional
processing which takes place in the adrenal
medulla which is required for the trophic activity.
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In the mouse MPTP-lesion model, bFGF was
found to protect against dopamine depletion when
applied at the same time or shortly after MPTP.
Although it has a protective effect, it did not restore
depeletion when applied long after MPTP. TH is
also protected; TH-immunoreactive fibers recover
only immediately adjacent to the bFGF-
impregnated gelfoam, but TH activity recovers
bilaterally. It was noted that bFGF binds strongly to
glial cells/146/.
Studies on the mechanisms of action of adrenal
medulla grafts were described by Becker and
Curran /8/. These experiments focused on two
topics: first, the relationship between effects of
adrenal medulla grafts and changes in striatal
dopamine metabolism, and second, the possible
role of changes in blood-brain barrier permeability
in the functional effects of adrenal medulla grafts.
Adrenal medulla grafts have been shown to cause
blood-brain barrier permeability/116/. Curran and
Becker /22/ showed that the behavioral response to
adrenal medulla grafts, especially the reductions in
amphetamine-induced rotation, are associated with
an increase in permeability of the blood-brain
barrier to dopamine. Additional studies by this
group /142/, comparing adrenalectomized and
normal rats with unilateral 6OHDA lesions of the
SN, have shown that adrenal medulla grafts appear
to function through at least two separate
mechanisms to decrease apomorphine-induced
rotation. The first, which is abolished by
adrenalectomy, appears to be associated with
increases in blood dopamine and is similar for
animals that receive grafts of adrenal medulla and
sciatic nerve or sham transplantation. The second is
a specific effect of adrenal medulla grafts, which is
similar in adrenalectomized and normal animals.
Since decreases in amphetamine-induced rotation,
rather than apomorphine-induced rotation, appear
to be related to changes in blood-brain barrier
function, it appears likely that adrenal medulla
grafts can induce changes in behavior through more
than one cellular mechanism.
A theme which was developed throughout the
meeting was the possibility of improvements in the
efficacy, as well as the survival, of chromaffin cells
in transplanted adrenal medulla. Transplantation of
adrenal medulla is an area which has been
motivated by two ultimate goals; first, the
treatment of Parkinson’s disease /41,50/, and
second, the use of adrenal chromaffin cell implants
for the treatment of intractible pain /117,119/.
Studies related to Parkinson’s disease will be
discussed in more detail below, and studies in
chronic pain will be described in the concluding
section on new models and applications.
A thorough review of the effects of adrenal
medulla autografts, including the multi-center trial
and registry data, was presented by Goetz /50/.
Although positive effects of adrenal medulla grafts
in patients with Parkinson’s disease have been
reported without the use of any of these additional
methods to enhance cell survival, the effects of
these grafts are relatively modest. There were
substantial improvements for up to one year, but
several of the symptoms which had shown earlier
improvement began to deteriorate after extended
periods. Most of the beneficial effects disappeared
after two years. There was, however, a significant
increase in total "on" time, which remained
significantly improved four years after
transplantation. One unanswered question is
whether the increase in "on" time represents a
simple change in the temporal pattern of on-off
cycling, as opposed to an improvement in function
which is perceptible to the subjects only during
certain periods of the on-off cycle. It is conceivable
that patients interpret periods of improved function
as "on" time, rather than as improved function
during "off" periods.
Garcia-Flores /45/ has also conducted long-term
studies of patients with adrenal medulla grafts, and
reported data which were generally consistent with
the results reported by Goetz/50/, notwithstanding
differences in methods of evaluation. Whereas
Goetz /50/ reported on overall mean changes in
performance scores, Garcia-Flores /45/
concentrated on the responses to treatment in
individual patients. Four-year follow-up data were
available for 17 patients. Of the original 24 patients
in the study, five had died and two others were lost
to follow-up. Two patients showed a substantial
long-term improvement; these patients were
distinguished by early age at onset of the disease
(24 and 41), and neither had received regular L-
DOPA treatment. Parenthetically, it might be
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mentioned that these characteristics are consistent
with a possible diagnosis of striatonigral
degeneration (see section on "substantia nigra
grafts"). Four additional patients showed no
improvement as compared to baseline disability,
but did not show progressive deterioration,
suggestive of a possible slowing in the progression
of the disease. The remaining patients showed no
apparent effect of the transplantation procedure,
and in these patients there appeared to be a normal
continuing disease progression. In addition,
numerous surgical and medical complications were
seen. These included some suggestions of possibile
deleterious effects of the adrenalectomy, such as
decreased cortisol, increased incidence of diabetes
mellitus, and a possible reduction in stress
tolerance. In this latter study /45/, therefore,
beneficial effects of adrenal medulla
transplantation were detected, but substantial long-
term improvement was seen only in a minority of
patients, who were atypical.
In the seven published autopsies, few or no
surviving chromaffin cells have been found. These
clinical data taken together suggest that: (i) at least
some of the effects of adrenal medulla grafts may
be due to non-specific mechanisms which do not
require chromaffin cell survival; (ii) technical
improvements which result in increased cell
survival may lead to improvements in the
performance of these graftz clinically, and (iii) the
high frequency of side-effects is a major problem
for this procedure. Nonetheless, adrenal medulla
transplantation continues to be attractive, in part
because it eliminates the problem of obtaining fetal
tissue.
Basic studies: Methods to improve performance
The improvement of chromaffin cell graft
performance and survival was addressed in several
experimental studies. One of the most consistent
themes was the enhancement of chromaffin cell
survival by methods which are intended to increase
the delivery of NGF to chromaffin ceils. These
studies took several forms, involving delivery of
NGF through chronic pumps /46,102,103/, co-
transplantation of ceils genetically modified to
deliver NGF /20,107/, co-grafting of peripheral
nerve or other tissues in combination with
chromaffin cells /4,23,85,90,151,156/, and the
development of methods to enhance penetration of
NGF through the blood-brain barrier/43,51/. Some
of these methods, including co-transplantation with
peripheral nerve fragments, and direct delivery of
NGF into the brain using mechanical pumps, are
being employed in clinical trials of adrenal medulla
transplantation in humans.
Cunningham et al. /20/ reported on the genetic
modification of Type 1 astrocytes purified from rat
cerebral cortex to constitutively express mouse
NGF. These genetically-modified astrocytes release
NGF into the medium at a rate more than 10-fold
higher than comparable non-modified astrocytes.
Effects of co-transplantation of these astroeytes
with adrenal chromaffin cell suspensions were
examined. Chromaffin ceils transplanted alone
resulted in survival of a mean of 221 -,- 129 TH-
immunoreactive cells after 10 weeks, as compared
to 99 5 cells in animals with adrenal medulla plus
normal astrocytes, and a mean of 1168 -,- 143
surviving TH-positive ceils in the animals that
received adrenal medulla plus NGF-modified
astrocyte grafts. The chromaffin ceils in the NGF-
astrocyte co-graft group also showed an increased
expression of a neuron-like phenotype, including a
large soma and extension of TH-positive processes.
Along the same lines, Patterson and coworkers
/107/ described the use of fibroblasts genetically
engineered to produce NGF for co-transplantation
with adrenal medulla. When adrenal chromaffin
cells were transplanted into the striatum of adult
rats in combination with these NGF-fibroblasts, the
chromaffin cells expressed microtubule-associated
protein (MAP)-2, NGF receptor, neurofilament,
and TH. The cells exhibited greatly enlarged soma
size and extensive process development. The
number of surviving TH-positive cells was
increased 2.5-fold as compared to chromaffin cells
co-transplanted with normal control fibroblasts. As
in other studies of NGF effects on adrenal medulla
grafts, the outgrowth of processes was largely
confined to within the graft.
An additional advance in the possibility of
enhancing chromaffin cell survival by co-
transplantation was reported by Date and
coworkers/23/, based on studies which had shown
that transection of peripheral nerve increases the
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synthesis of NGF (e.g., /58/). Chromaffin cells
were transplanted into the brain either alone, or in
combination with sciatic nerve that had either not
been previously transected, or that had been
transected one day previously. The number of
surviving chromaffin cells was increased
approximately two-fold by the non-transected
nerve, and increased about three-fold by the co-
grafts of nerve that had been previously transected.
Measurements of TH immunostaining intensity
adjacent to the grafts showed that the adrenal
medulla + pretransected nerve grafts increased
immunostaining in the 0.3 mm x 0.3 mm segment
of host striatum immediately adjacent to the grafts,
but not further away. The immunostaining intensity
was increased, as compared to the adrenal medulla-
only animals, by both the pre-transected and non-
pretransected nerve co-grafts. This represents a
possible further refinement of the peripheral nerve
co-grafting method, which is potentially applicable
to clinical studies.
An interesting potential method for delivering
NGF to the brain by conjugation to an anti-
transferrin antibody was described by Granholm
and coworkers /43,51/. This method could be
applicable to promoting the survival of adrenal
medulla grafts, in addition to other possible
applications of NGF or other growth factors which
require delivery to the central nervous system. The
effects of NGF delivered by this method were
measured by changes in the size of intraocular
grafts of fetal septal tissue. The blood-brain barriar
was shown, by exclusion of Evan’s blue dye, to
have developed in these grafts. Stain was found in
blood vessels in the host iris and in the grafts, but
not in the graft neuropil. Animals received either
NGF alone, NGF-antibody conjugate, antibody
alone, or no treatment by a single injection every
two weeks. It was reported that grafts in animals
treated with the NGF-antibody conjugate grew
significantly larger. These grafts also expressed
more NGF immunoreactivity and a larger number
of choline acetyltransferase immunoreactive
neurons than grafts in the controls. NGF
concentrations in brain were measured, and
preliminary results also suggested some elevation.
Gash/46/discussed preliminary findings of the
effects of infusion of NGF followed by
autotransplantation of the adenal medulla in an
MPTP-lesioned primate. This study employed a
bilateral infusion model, in which MPTP was
infused separately into both carotid arteries. In
contrast to the unilateral MPTP infusion, or
systemic injection of MPTP in which both sides are
simultaneously and similarly lnsioned, the bilateral
model allows for the possibility of the animal to
recover from the first set of lesions before the other
side is lesioned via the second carotid artery. In this
first animal tested, a catheter was placed into the
putamen to infuse NGF, and one week later adrenal
medulla autografts were placed around the catheter.
The NGF infusions caused an increase in motor
activity, analagous to decreased bradykinesia, and
an improvement in ratings of motor impairment.
The adrenal medulla grafts did not produce a
substantial additional effect. The ratings slowly
deteriorated when the NGF infusions were
discontinued. Thus, in this first animal, the
improvement observed was related more to the
NGF infusions than to the transplantation of
adrenal medulla (also cf. /19/). This finding,
although so far reported for only a single animal, is
reminiscent of the report by Pezzoli et al./110/in
which NGF infusions increased the efficacy of
adrenal medulla grafts, but were similarly effective
when combined with grafts of other types of tissue,
such as adipose tissue or poripheral nerve.
An additional study on adrenal medulla grafts in
primates, reported by Bakay and coworkers /4/,
examined co-grafts of adrenal medulla and sural
nerve, as compared to controls that received sham
surgery. Following unilateral MPTP administra-
tion, Parkinson-like symptoms were evaluated by a
variety of techniques. These techniques included
rotational behavior and an operant assessment of
movements task, in which time required for an
animal to activate a touch-sensitive screen in
response to a visual cue was measured. The co-
grafts caused an 84% decrease in apomorphine-
induced rotation, as compared to a 52% decrease in
the sham-operated controls. The decreases were
seen over the course of 3 months after surgery, and
were stable for up to one year. Improvements in
movement times were seen in the co-grafted
animals and in only one of the sham-operated
controls. Although this study did not compare co-
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grafts to adrenal medulla-alone grafts, it does
suggest that adrenal medulla/peripheral nerve co-
grafts can produce behavioral improvements in
hemiparkinsonian primates.
Several clinical studies addressed the issue of
improving the performance of adrenal medulla
grafts. One possibility, which has largely been
ignored in the basic literature, is the perfusion of
adrenal medulla prior to transplantation /86,87/.
Perfusion of adrenal medulla prior to
transplantation will remove blood cells which may
promote graft rejection, and might accomplish
some of the same goals as isolation of chromaffin
cells prior to transplantation, as reported by
Schueler and coworkers /123/. Lopez-Lozano
/86,87/described clinical studies in which patients
received grafts of adrenal medulla which had been
perfused with a calcium and magnesium-free
buffer. Patients who had received perfused adrenal
medulla grafts had been followed for up to three
years, and were found to have shown improvement
on the Unified Parkinson’s Disease Rating Scale
(UPDRS) and the Hoehn and Yahr Scale over the
course of the first seven months after
tranplantation. From seven months to three years
after transplantation, some patients maintained the
improvements, and for others the improvements
were slowly lost, although the overall mean scores
were fairly stable over the seven month to three
year follow-up. Data reported by Lopez-Lozano
/85,86/ on co-grafts of adrenal medulla with
peripheral nerve suggested that the major
difference from the grafts of adrenal medulla alone
was that the phase of gradual improvement lasted
longer, for approximately 9 12, instead of seven,
months after surgery.
Watts and coworkers /150,151/ reported on
initial results from three patients (ages 45 55) who
had received adrenal medulla/intercostal nerve co-
grafts. Patients received grafts into two sites in the
caudate and one site in the putamen. Patients
developed slightly increased dyskinesias, and
otherwise tended to show improvements which
were somewhat variable. In patient number two, a
substantial improvement in relative "on" and "off"
times was noted. There was no change in the third
patient, who had been followed for only three
months. On timed motor tests, patients number one
and two were improved somewhat in pronation/
supination, hand/arm movements, and a
stand/walk/sit test, but only slightly improved in
finger dexterity.
Data from Madrazo and coworkers /90/ on four
patients, ages 41-51 years, who had received
adrenal medulla and peripheral (intercostal) nerve
co-grafts, were presented by Franco-Bourland.
Although some improvements were seen in all
patients, in three of the four the improvements in
UPDRS scores were considerably less than the
mean improvement seen in a series of 18 patients
who had received adrenal medulla-only grafts.
These improvements were said to be similar to the
improvements seen in poorer responders to adrenal
medulla-only grafts. Substantial improvement,
similar to the mean improvement in patients with
adrenal medulla-only grafts, was seen in only one
patient. Taken together, the three studies /85,90,
150,151/do not provide, at least up to the present
time, strong support for the possibility that the
clinical effects produced by the co-grafting method
are more substantial than the changes produced
after adrenal medulla grafts alone.
The final presentation, from Olson et al. /103/
presented by Hoffer, described a possible
alternative method for improving the clinical
effects of adrenal medulla grafts by combining the
grafts with infusions of NGF. Data from three
patients were presented. The first patient, who has
already been described in a published paper,
showed some prolonged improvements/102/. In a
second patient, there were some improvements,
including a dampening of "on"-"off" cycling, but
these had disappeared after about six months. In a
third patient, who had so far been followed for only
about six weeks, there were substantial
improvements in walking, standardized tests of
motor function, and Brightschaft potentials on the
operated side. These patients will continue to be
monitored.
In addition to the possibility of increasing
chromaffin cell survival and effiicacy by co-grafts
or NGF administraton, two additional techniques to
increase chromaffin cell survival were described. A
very interesting study /76,123,124/ demonstrated
convincingly that purified bovine chromaffin cells
survived transplantation much better than a mixed
VOLUME 4, NO. 2, 199378 W.J. FREED AND J. M. ROSENSTEIN
cell preparation from bovine adrenal medulla.
Bovine adrenal medulla ceils were dissociated and
transplanted into the striatal parenchyma of rats
immunosuppressed with cyclosporin A. Purifed
chromaffin cells were prepared by Percoll gradiant
separation and differential plating. Three different
cell preparations were employed: (a) The mixed
preparation of bovine adrenal medullary cells; (b)
the purified chromaffin ceils, and (c) a reconsituted
preparation, consisting of both chromaffin cells and
the other medullary ceils. It was found that cell
survival was greatly superior in the purified
chromaffin cell preparation, as compared to both
the original mixed cell preparation and to the
reconstituted preparation of chromaffin cells plus
non-chromaffin cells.
Another technique, described by Dubach et al.
/28,29/, involved the transplantation of adrenal
medulla tissue in elongated "ribbons", using a
method which allowed the tissue to be delivered
into the brain so that the tissue was in contact with
host brain along its entire length without
deformation/30/. Behavioral effects of the grafts
were examined in primates using a rotational
behavior model/28,29/which involved assessment
of behavioral changes in individual subjects with
time-series analyses. Transplantation of adrenal
medulla using earlier methods, which result in poor
tissue survival, did not cause significant decreases
in rotational behavior. There were no
improvements in behavior in the first two animals
receiving adrenal medulla grafts by the ribbon
method; however, in four subsequent animals
which received more widely distributed ribbon
grafts with longer total graft lengths, there were
significant behavioral improvements. The
behavioral improvements were associated with the
total length of the graft ribbons. Thus, a relatively
simple surgical technique which increases graft-
host contact resulted in greatly improved tissue
survival, reinforcing the conclusion that adrenal
medulla grafts can produce behavioral changes
which are related to the number and distribution of
surviving chromaffin cells/29/.
Although so far preliminary results of clinical
co-grafting studies are not especially promising,
there are several techniques which have been
described for improving the functional effects and
survival of adrenal medulla grafts which could be
employed clinically. These give several possible
avenues for improving the performance of these
grafts, perhaps even including optimizing the
method by combining various methods such as
improved surgical technique /28-30/, purified
chromaffin cells or perfusion/86,87,123/, and co-
grafting/23,156/or possibly a method for delivery
of NGF/20,46,102,107/. Such an approach might
very well result in dramatically improved graft
performance.
SUBSTANTIA NIGRA GRAFTS
Information presented at the meeting pertaining
to substantia nigra (SN) gratis ranged from basic
studies of the development of dopaminergic ceils to
long-term studies of clinical efficacy.
Basic studies
Several presenters reported on the effects of
growth factors on in vitro characterization of the
properties of human ventral mesencephalon/19,26,
128/. For example, Dong et al. /26/reported that
treatment of primary cultures of human second
trimester fetal mesencephalon with bFGF or with a
combination of bFGF and NGF caused an increase
in the number of neuron-specific enolase immune-
reactive cells, with no change in the number of
GFAP-positive ceils, and a two-fold increase in
catecholamine content. NGF alone had no effect,
but potentiated the effect of bFGF.
Although the development of rodent
dopaminergic cells has been studied extensively,
there has been relatively little work on the
development of human dopaminergie meseneeph-
alic neurons. Silani and coworkers /128/ studied the
development of human fetal ventral meseneephalon
from 6 to 11 weeks. Neurite extension from TH-
immunoreactive cells took place from 8 to 9 weeks;
at 8 weeks in vivo the ceils began to form a
crescent-shaped structure; by 9 weeks the
dopaminergic afferentation of the striatum begans
to form, and by 11 weeks most TH-positive
neurons had developed processes. The ratio of
neurons to GFAP-positive astroglia was
approximately 0.7 to 1, and the number of TH-
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positive cells comprised between 1 and 2.5% of the
total neurons. Effects of various growth factors on
the number of TH-positive neurons surviving and
neurite extension in vitro were examined. In
agreement with Dong et al./26/both survival and
neurite extension were increased by bFGF, but not
by several other growth factors, bFGF also induced
glial cell proliferation, and a specific adherence
between TH-positive neurons and GFAP-positive
astrocytes was noted, raising the possibility that the
effect of bFGF on dopaminergic neurons is
mediated by an effect on glial cells.
Stromberg and coworkers /139/ reported on
studies showing that the outgrowth of fibers from
human mesencephalic cell grafts in rats is specific
for the appropriate target brain regions. A study
was described in which human fetal tissue from the
SN, locus coeruleus, and arcuate nucleus was
transplanted to the striatum of rats with unilateral
SN lesions induced by 6OHDA. Only the SN grafts
produced reductions in rotational behavior and
electrophysiological inhibition of host neurons.
There was a substantial ingrowth of neurites from
the SN grafts into the striatum. For the locus
coeruleus grafts, there was some ingrowth of fibers
into the host brain, although very slight, while no
ingrowth of neurites from the arcuate nucleus grafts
into host striatum was seen. This study reinforces
the conclusion that the effects of SN grafts are
specific and are related to reafferentation of the
host brain, at least in the 6-hydroxydopamine
(6OHDA)-lesioned rat model.
Interesting data on the effects of SN grafts in
rodent models were also presented. Hattori and
coworkers/55/, for example, employed running on
a variable speed treadmill to assess motor abilities
following SN lesions and transplantation. Normal
control rats, without lesions, were able to run at any
speed up to the maximum (1800 cm/min). Lesions
decreased the speed at which the animals were able
to run, and SN grafts produced a partial recovery of
running speed. The experience of running was
found to cause increases in extracellular dopamine
as measured by in vivo microdialysis. A study
presented by Kondoh and Low /75/ showed that
dopamine release in the striatum in animals with
SN grafts is regulated by glutamate agonists in a
manner similar to that-seen in normal striatum,
although the effects were smaller. For example, 10
laM of kainic acid induced dopamine release in
normal striatum, whereas 100 I.tM kainic acid was
required to induce dopamine release in animals
with SN grafts. In normal striatum, the glutamate
uptake inhibitor dihydrokainic acid induced a 21-
fold increase in dopamine release, while a 3.5-fold
increase was induced in animals with SN grafts.
Another study, presented by Triarhou and
coworkers /145/, examined behavioral deficits in
weaver mutant mice, which have deficiencies in the
nigrostriatal system, as well as motor abnormalities
including postural and gait instability. The weaver
mutation was maintained in mice of two different
strains, derived from BALB/c and C57B1/6 mice.
Behavioral abnormalities observed were different
for the two mouse strains. Grafts of dissociated
mesencephalic dopaminergic neurons induced
behavioral improvements, which depended upon
the mouse strain in which the weaver mutation was
maintained. Further studies may help to elucidate
the reasons for the different behavioral
abnormalities and the mechanisms through which
the grafts produce behavioral improvement.
Yanai and colleagues /162/ investigated
rotational behavior in domestic fowl, with
unilateral lesions of the avian SN equivalent
induced by 6OHDA. In these animals, strong
contralateral rotation was induced by apomorphine,
although relatively higher dosages were used (3
mg/kg), as compared to the minimum dosages
needed to induce rotation in rats (less than 0.05
mg/kg). Amphetamine did not, however, induce
locomotor activation or rotation in-these fowl.
Following transplantation of embryonic (E7) SN
equivalent into the striatum in the form of cell
suspensions, rotational behavior was decreased by
about 6% after one week, and by more than 90%
after one month. These studies provide a model in
which the effects of grafts on apomorphine-induced
rotation are very large, and the authors point out
that a signficant advantage in the use of fowl is the
availability of large numbers of embryos at the
exact stage of development required.
A refinement in the traditional rotational
behavior model of transplantation was described by
Schallert et al. /122/, based on a method for
examining the behavior of animals with unilateral
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SN lesions. Animals were held, so that only the
contralateral forelimb was supporting the animal’s
weight. It was shown that the animals were unable
to initiate steps with their contralateral forelimb,
but when the animal was moved forward manually,
the contralateral limb was able to step to keep pace.
The ipsilateral forelimb was able to step normally.
Amphetamine and apomorphine both increased the
stepping rate of the ipsilateral forelimb, but the
contralateral forelimb was unable to initiate steps
even after amphetamine or apomorphine. Thus,
during rotational behavior tests when the animal is
allowed to move freely, the contralateral limb
makes only catch-up steps, which is the cause of
the turning behavior. In amphetamine-induced
rotation, the ipsilateral limb tends to make
movements in the ipsilateral direction, while in
apomorphine-induced rotation, the ipsilateral limb
tends to make crossing movements in the
contralateral direction. It was noted that, in animals
with unilateral SN lesions, "The ipsilateral forelimb
is capable of initiating stepping movements that
have major weight shifting consequences whereas
the contralateral forelimb almost exclusively makes
reactive steps to regain support of a displaced
center of gravity..." /122/. Thus, these behavioral
findings tend to validate the rotational behavior
model as an indicator of Parkinson-like akinesia or
bradykinesia; nonetheless, these data suggest that
measurement of the ability of the contralateral
forelimb to initiate stepping movements would be
an important means of assessing the potential
efficacy of various therapeutic modalities in the
unilaterally-lesioned rat model.
Taylor and coworkers /143/ presented data on
the relationship between the initial severity of
Parkinson-like symptoms induced by MPTP lesions
in primates and the degree of spontaneous recovery
and functional improvement induced by SN grafts.
Each of 70 animals was assigned a score of "0" to
"4", based on ratings and measurements of
behavioral impairment following MPTP
administration. The score of "0" was used for
normal, untreated subjects, and "1" represented
subtle deficits in object retrieval but not gross
motor deficit. Scores of "2" through "4"
represented increasingly severe parkinsonian motor
impairment. The more severe the initial deficits,
the less rapidly the animals showed spontaneous
recovery. Monkeys with ratings of "1" showed
spontaneous recovery within one month, while
animals with scores of "4" did not recover during 5
months of assessment. Improvements after SN
transplantation were observed in category "1", "2",
"3", and "4" subjects. Improvements were not seen
after control surgical procedures. Category "4"
subjects tended to have medical complications and
were difficult to maintain; SN grafts were found to
increase the percentage of category "4" subjects
which survived for more than three months. Thus,
there was evidence of functional improvements in
primates receiving SN grafts into the caudate
nucleus, but control procedures including sham
surgery, transplantation of cerebellum into the
caudate nucleus, and transplantation of SN into the
cortex did not produce improvement.
Prior studies by Brundin and coworkers/14,15/,
using grafts of dissociated human mesencephalic
cells, had found that tissue from human donor
embryos of more than 11 weeks of fetal age were
not effective when transplanted into immuno-
suppressed rats. In these experiments, tissue from
donors of age 6.5-9 weeks was effective, while
tissue from 11-19 week gestational donors was not.
The cut-off age for human fetal donors must
therefore be around 9 weeks for dissociated cells. It
was generally assumed, however, that it would be
possible to use slightly older donors, possibly 10 or
11 weeks, if solid grafts were used. This
assumption was based on data suggesting that rat
tissue can be approximately one day older when
using solid tissue grafts /129,140/. A paper was
presented by Freeman et al. /42/ in which this
question was studied directly, using xenografts
from human donors to immunosuppressed rat hosts.
Donors ranged from 4-5 weeks (7 9 mm crown-
rump length) to 10.5 weeks of fetal age. Data were
evaluated in terms of survival of TH-
immunoreactive cells and host reafferentation. It
was found that dissociated cell grafts survived best
when the donors were between 5 and 8 weeks of
age (E34 to E56). Poor cell survival was obtained
when the donors were older than 9 weeks (E65).
For solid tissue grafts, however, E37 donor tissue
resulted in only modest cell survival. The best cell
survival was obtained with donors between 6 and 9
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weeks (E43 to E65). No survival was obtained for
grafts older than E72, or slightly greater than 10
weeks. These data provide the first direct
comparison of solid and dissociated cell grafts in
terms of age requirements for cell survival, and
confirm previous data suggesting that tissue no
older than 9 weeks for dissociated grafts and 10
weeks for solid grafts must be use,,. r anything,
these data suggest that the age limit for solid tissue
grafts is somewhat earlier than previously thought.
It seems probable, therefore, that tissue of fetal age
11 weeks or greater is not likely to reafferent host
striatum when used for clinical studies.
One issue which is a concern regarding the use
of fetal SN grafts in human patients, is whether the
grafts may be damaged by drugs especially L-
DOPA- which are routinely administered to
patients with Parkinson’s disease. Steece-Collier
and coworkers /135,136/ reported that L-DOPA
impairs the survival and neurite outgrowth from
primary dopaminergic neurons in tissue culture.
Effects of chronic L-DOPA treatment on SN grafts,
made by injection of solid fragments of SN directly
into the striatum, were also examined.
Morphological development of the TH-
immunoreactive neurons seemed to be impaired, in
terms of neurite development and size of the
neurons, although the number of surviving neurons
was not decreased. Steece-Collier /136/ presented
additional data on the effects of L-DOPA treatment
on SN grafts. It was found that the effects of SN
grafts on amphetamine-induced rotation, measured
six weeks after transplantation, were greatly
diminished in animals that had received chronic
administration of 50 mg/kg of L-DOPA i.p., twice
per day, as compared to saline-treated controls. The
administration of L-DOPA was discontinued after
six weeks. In the saline-treated controls, the
decreases in rotational behavior were maintained
when retested at 12 weeks. In the L-DOPA-treated
animals, six weeks after withdrawal there was a
non-significant reduction in rotation, although not
to the level of the controls. When data from
individual animals was examined, it appeared that
there was a tendency for recovery in half of the
animals, but the other half of the animals did not
recover. Van Muiswinkel and coworkers /147/
found that, although L-DOPA treatment of
dopaminergic neurons in culture induced signs of
degeneration (a loss of dopamine uptake), this
effect could not be duplicated by chronic
administration of a D2 receptor agonist. It thus
remains a strong possibility that the efficacy of SN
grafts may be impaired by L-DOPA treatment, at
least under certain conditions (also cf. /10,147/).
Discontinuation of the L-DOPA treatment may not
invariably result in the reversal of this impairment.
There was also some consideration of methods
to improve the effects of SN grafts, using animal
models. Collier and coworkers /19/ described
experiments showing that sciatic nerve co-grafts
enhance the effects of SN grafts. Co-culturing
experiments with fetal neurons, and studies of
polymer-encapsulated sciatic nerve in aged animals
in combination with SN grafts, suggested that
sciatic nerve produces substances with trophic
effects on dopaminergic neurons. Experiments by
Yurek et al. /163/ examined the possibility that the
efficacy of SN grafts could be enhanced by using
both intranigral and intrastriatal SN grafts, and
reported that animals with grafts in both regions
showed a more rapid recovery than animals with
grafts in only the striatum. Sladek and coworkers
/131/ examined the effects of combined fetal SN
and striatum in primates. Although neuronal
survival was not markedly enhanced by the co-
grafting procedure, there were increases in
dopamine concentrations adjacent to the grafts,
suggestive of a possible recovery of host
dopaminergic systems. Taken together, these three
experiments /19,131,163/ suggest that it may be
possible to improve the efficacy of SN grafts by
various procedural or surgical modifications.
Gervais and Vawter /48,148/ presented
information related to the development of ethical
guidelines and the unique concerns related to the
transplantation of fetal tissue. One set of guidelines
which may serve as a model is the cadaveric
donation framework. These guidelines treat the
fetus as a cadaver but do not, however, address the
possible concerns or role of the mother as a donor.
Additional provisions may be needed related to the
special circumstances of fetal transplantation, to
provide for protection of both the fetus and the
mother. Details of the guidelines that have been
proposed or set up for various countries were
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described and compared. These guidelines, in
general, tend more toward treating the mother as a
living donor. A major issue is the provision for
varying degrees of insulation in information
transfer, regarding the separation of donors,
researchers, and patients. Another issue is the
possibility of modifications to the abortion
procedure that would be required for tissue
donation, including testing of blood and tissue. It
was suggested that a complete set of guidelines for
fetal tissue transplantation would include aspects of
both the cadaver donor framework as well as the
living organ donor framework.
Clinical trials
Data on two human patients with MPTP-
induced parkinsonism who had been followed for
two years after receiving fetal tissue grafts were
presented by Widner /154/. Each of the two
patients was transplanted with a large amount of
tissue, consisting of the ventral mesencephalon
from 6-7 human fetuses. Following the surgery,
patient #1 was maintained on a stable dose of L-
DOPA, while the dose of L-DOPA for the’second
patient had to be decreased by 75% due to side
effects. Gait, as measured by number of steps, was
substantially improved in patient #1. Patient #2 did
not have a severe gait problem, and in this patient
the grafts produced no changes in gait. Rigidity
improved slowly over the two year observation
period, and continues to show a trend toward
improvement. Stop-start movement speed also
showed a similar pattern of slow improvement over
the course of the two year observation period. This
unique study of transplantation in MPTP-induced
parkinsonism may comprise an important bridge
between animal and human studies. For example,
interpretation is not complicated by continuing
progressive degenerative changes which occur in
idiopathic Parkinson’s disease. Such continuing
changes not only complicate the measurements of
outcome, but also could conceivably result in
progressive damage of the implanted tissue.
Another advantage of MPTP-induced parkinsonism
in humans for the study of transplantation is that
the degenerative disease process present in the
patients’ brains may be relatively less widespread.
Three patients reported by Dymecki and
coworkers /34/ received fetal tissue grafts from 11-
12 week getstational donors into the head of the
caudate nucleus using a method similar to the
Madrazo /91/ technique but with a specially
designed instrument. These patients had been
followed for 30, 20, and 12 months. Improvement
according to a number of parameters was observed
starting 3 to 6 months after surgery and was
sustained for the entire observation period. This
study included assessments of motor performance
using timed tasks; for example, there were
improvements in foot lifting, pronation/supination,
and finger dexterity of the order of 30 to 50%.
Percentage of the day spent in "off" phase
decreased from 55% before transplantation to 17-
18% from 9 to 30 months after transplantation.
Lindvall /84/ discussed the results of fetal SN
transplantation, using dissociated cell grafts, in four
patients with idiopathic Parkinson’s disease. The
two patients with MPTP-induced parkinsonism
described by Widner (see above;/154/) were also
discussed. Each patient received grafts from several
fetal donors. Some of the earlier results from three
of the patients have been described in prior
publications/82,83/. Patients numbers 3 and 4 both
received grafts into the putamen only. Patient #3
has shown significant improvement. Patient #4
especially has shown continued improvement from
one to three years after transplantation; this patient
now has no "off" periods. Rigidity has decreased,
but this effect did not begin to appear until one year
after transplantation. Gait was not improved, and
tremor has not improved in any of the patients.
Thus, there seem to have been some effects, such
as decreased rigidity, that were not seen until more
than one year after transplantation. Interestingly,
the disease process seems to have continued, as
measured by decreased fluorodopa uptake in
positron emission tomography (PET) scans or by
the progressive deterioration in tremor and gait,
even while progressive improvement was observed
in other measures such as "on"-"off" periods and
rigidity. These data suggest that graft function may
not be adversely influenced in concert with the
progression of the disease, and that SN grafts may
produce therapeutically significant improvements
in Parkinson’s disease.
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Freed /39/ reported on clinical changes in
patients that had received fetal SN grafts. The first
of these patients had been followed for nearly four
years. Alternate patients were immunosuppressed
or not immunosuppressed. Clinical improvement
was observed in 5 of 7 patients overall, most of
whom received bilateral grafts into 12 to 14 sites in
the putamen, with tissue obtained from a single
embryo. Improvements were seen in rapid
alternating movements, postural control, speech,
and "on" durations, which occurred gradually over
the course of several months. In the first patient,
there were modest signs of clinical improvement
during the first year after transplantation, although
walking speed did not improve and in fact was
slightly worse during the first year. Between 15 and
45 months after transplantation, however, there was
a marked progressive improvment in walking
speed. This may have corresponded to evidence of
continued transplant development, from lSF-DOPA
PET scanning, between 9 and 33 months. The slow,
long-term improvement seen in the first patient is a
very interesting observation.
Molina and coworkers reported on studies of
transplantation of fetal mesencephalic tissue into
patients with Parkinson’s disease, including long-
term studies of 30 patients who had received grafts
into the caudate via a transfrontal open surgical
approach/94/and four patients who had received
stereotaxic implantation of dissociated cells into
the caudate and putamen/93/. In the thirty patients
with grafts to the caudate, there were clinical
improvements, including changes in "on" and "off"
periods, changes in L-DOPA dosages, and changes
in UPDRS scores, which persisted for the 26 53
months of postsurgical follow-up. The largest
changes in UPDRS scores were seen during the
first three months after transplantation, following
which scores were stable or showed further small
improvements for up to three years/94/. The four
patients with stereotaxic dissociated cell grafts had
been followed for only a few months. For this
procedure also, improvement was seen in several
measures including, for example, rigidity scores
and "on" -"off" fluctuations. Surprisingly, the
improvements developed very rapidly, with
considerable changes occurring over 2 3 months,
and some improvements even after 30 days. There
was no suggestion of an improvement occurring
over a long period akin to that reported by Widner
et al. /154/, Lindvall et al. /84/, or C. Freed et al.
/39/.
Hitchcock and coworkers /61/ (also el. /57/)
reported on 12 patients that received grafts of
ventral mesencephalon from human donors of 11 to
18 weeks gestational age, implanted into a single
site in the right caudate nucleus. Note that the age
of the donor tissue in this study appears to exceed
the optimal range. The range of patient ages was
from 41 to 67 years, with 10 of the 12 patients aged
53 to 60 years. All implantation procedures were
performed stereotaxically, and the patients were not
immunosuppressed. Using the Webster rating scale,
which rates motor dysfunction, three of the 12
patients showed improvement after three months
which was sustained when retested at 6 and 12
months after transplantation. The other nine
patients either showed no change or showed
improvement after 6 months followed by
deterioration to baseline levels of performance or
slightly below. Interestingly, timed tests of motor
function showed clear group improvements, in
some cases including improvements that were not
reflected clinically. For example, in one patient,
whose functioning according to the Webster scale
improved but deteriorated back to baseline levels
from 6 to 12 months, performance on
pronation/supination remained improved. Group
performance on the pronation/supination test
showed a clear tendency for contralateral
improvement (cf. /57/). In other experiments,
patients received unilateral grafts into the putamen,
the caudate and putamen, or bilaterally into the
heads of both caudates. In addition, a group of
patients that did not receive surgery was followed
as a "control" or comparison group, for ptrposes of
comparison with the operated patients. There was
no clear indication of superiority of any of the four
implantation site regimens. A particularly valuable
aspect of this series of studies is that it employed
videotapes which were blindly rated by
independent neurologists. One patient has died;
although results of the post-mortem examination
were not yet complete, no TH-positive ceils have
been found and some TH+ fibers around the graft
were seen.
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The final paper of the symposium, also on
transplantation of fetal SN into human subjects,
was given by Redmond et al./112/. This study had
several unique aspects, which were in some
respects advantages and in other respects were
drawbacks. First, this study is the closest
approximation to a controlled study to date. Half of
the patients served as non-operated controls for one
year, following which they received the same
transplantation surgery as the experimental group.
This does permit a direct comparison between the
groups; however, as discussed above, recent data
suggest possible effects which take place over the
very long-term (more than one year), and the one-
year crossover design would not allow these
changes to be detected. Second, the tissue used was
cryopreserved, which allows for donor-host
separation, screening, and scheduling. Tissue was
implanted into the caudate nucleus only, and all
patients received immunosuppression with
cyclosporin for 6 months after transplantation.
Patients were videotaped performing timed motor
tasks, while wearing a cap and gown to conceal
whether they had received surgery or were
controls. There were two series of patients; the first
received unilateral implantations into the caduate
nucleus from one 7-11 weeks gestational donor
each. The second series received tissue bilaterally
into the caudate nucleus from 1-3 donors of 9-11
weeks gestation. Preliminary results from patients
in the first series were reported. There were
improvements in the operated patients which were
consistent for several tasks, including walking,
pronation/supination, foot-tapping, and fist
clenching. These improvements exceeded those of
the controls. An interesting observation with
implications for other clinical studies was that
ratings using the UPDRS showed improvements in
the operated patients and also in the controls;
nonetheless, the improvements in the operated
group were somewhat smaller. Also, the controls
self-rated themselves as being considerably
improved, but the objective raters did not observe
as much improvement in the control group.
There was one death, which appeared to be
unrelated to the experimental procedure. Histology
of this brain revealed that the graft did not have
surviving TH-immunoreactive cells and, moreover,
that this patient had striatonigral degeneration, not
Parkinson’s disease. This latter observation can be
interpreted as raising an interesting caution. This
diagnosis represents a minority of the population of
patients with Parkinson’s disease. Nevertheless,
there are several factors which may substantially
increase the probability of including patients with
striatonigral degeneration in clinical transplantation
trials. It may be that patients with striatonigral
degeneration, who are unresponsive to L-DOPA,
show a relatively high probability of non-
responsiveness to therapy, and a correspondingly
high probability of meeting the selection criteria
(severe illness, unsatisfactory response to
conventional therapy) for inclusion in experimental
trials. Although patients with striatonigral
degeneration can be distinguished by a poor
reponse to L-DOPA, it is often not possible to
make this diagnosis reliably except by post-mortem
examination (cf. /33/). Patients with striatonigral
degeneration are also relatively younger than
patients with Parkinson’s disease (cf. /73/). In
several clinical trials, it has been considered
desirable to employ relatively young patients.
Several very young patients, in fact, have been
employed in clinical transplantation trials. The
tendency to include young patients may further
increase the probability of including patients with
striatonigral degeneration. Although it is not
impossible that dopaminergic tissue transplants
would improve function in patients with
striatonigral degeneration, such an improvement, of
course, would not have been predicted from the
literature on transplantation in animal models.
This latter study /112/ is certainly a potential
model of experimental design for future studies, in
terms of the controlled design, blind ratings of
quantifiable motor tasks, and consistency which
was permitted due to the use of cyopreserved
tissue. On the other hand, there were drawbacks to
this particular study, including the relatively short
(one-year) controlled evaluation period,
implantation of tissue into the caudate only, and the
use of donors which were in some cases of a
gestational age slightly exceeding what appears to
be optimal. The development of an effective
transplantation methodology is bound to be a
complex process which will involve improvements
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in procedures and experimental design over the
course of a number of clinical trials.
Several reports on transplantation in human
patients have employed tissue of a gestational age
which exceeds the optimum that would be expected
from studies of transplantation of human fetal
tissue into rat hosts. Freeman /42/ (see above)
presented data which suggest that it is not likely
that human tissue older than approximately 10
weeks gestational age would be effective. It is
therefore conceivable that the improvement in
some of the clinical studies is due to some factor
other than graft survival and host brain
reafferentation.
On the other hand, it is also possible that
:’-apse, are irrelevant for the clinical
improv, ".nt. This could be the case even for
younger ts.ue which does reafferent host brain and
even prodnces synapses, since improvement has
been observed in some studies using tissue more
mature than what would seem to be optimal. Since
the improvement to some degree (especially for the
near-term effects, i.e., up to one year) seems to be
generally similar for all of the transplantation
techniques, perhaps reafferentation is not
important. Another caveat should be pointed out as
well: The conclusion that clinical transplantation
will require tissue younger than 10 weeks is based
largely ota studies of human tissue transplantation
into rats, in vitro studies and examination of human
fetal tissue. Although this extrapolation is quite
reasonable, the possibility that survival and
development of more mature donor tissue can be
observed for transplantation of human tissue into
human brains, and especially into the brains of
patients with Parkinson’s disease where unusual
trophic interactions may be present, cannot be ruled
out entirely.
The one facet of clinical improvement that, so
far, has been reported only for transplants using
young donor tissue is the very long-term gradual
improvement observed between one and three
years aft(C)r transplantation, by Widner et al. /154/,
Lindval! et al./84/and C. Freed et al./39/. Each of
these studies used donor tissue younger than 10
weeks, which would be expected to be at least
capable of reafferenting host brain. Nonetheless,
there were other unique aspects of these studies
including transplantation into the putamen. It is
also notable that, in animals, the functional effects
which are observed following SN grafts generally
require tissue which is capable of growing new
dopaminergic fibers into the host brain. A
reasonable hypothesis then, regarding the clinical
results, is that the relatively short-term effects, seen
up to approximately one year, involve a mechanism
other than reafferentation of the host brain, as
generally similar effects can also be produced by
several types of fetal tissue transplantation and
even, at least to some extent, transplantation of
other tissues, including adrenal med..t and
superior cervical ganglia. A gradually-developing
improvement that continues over the very long
term, that is, more than one year after
transplantation, may be suggestive of effects which
involve the development of new connections
between graft and host brain. This hypothesis,
however, is far from confirmed and will require
considerable additional evidence.
NEW MODELSAND NEW POTENTIAL
APPLICATIONS
Nakao and associates /97/ presented data on
transplantation of superior cervical ganglia (SCG)
to the brain in animal models of Parkinson’s
disease. In rats, SCG from 2-3 day postnatal rats
was grown in culture for four to six weeks. For
transplantation, these cells were scraped off of the
culture dishes and resuspended, but not entirely
dissociated. Either SCG cells or sciatic nerve, as a
control tissue, was transplanted into the brains of
rats with unilateral lesions of the SN. Rotational
behavior was gradually decreased over the course
of 12 weeks, finally reaching a decrease of
approximately 70% as compared to the control
group. Excellent examples of grafts with numerous
surviving catcholaminergic cells were shown using
histochemical fluorescence. Wu et al. /161/ also
showed that the development of kindled seizures in
norepinephrine-depleted rats could be delayed by
SCG grafts into the amygdala and piriform cortex.
Five animals with substantially surviving grafts
showed a greater than four-fold increase in the
number of stimulations required to induce seizures,
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while no effect was seen in another five animals
with poorly-surviving grafts.
In primates, using the MPTP model, long-term
improvement in three monkeys was reported. This
was accompanied by a slight increase in plasma
homovanillie acid /70/. Convincing evidence of
long-term survival of the grafts after two years was
shown using catecholamine histochemical
fluorescence. In the primate studies, although
improvement was reported in the animals that had
received grafts, there was not a very clear
difference between the experimental and control
groups.
Itakura also presented data suggesting the
possible use of transplantation of stellate ganglia in
human patients with Parkinson’s disease/69/. Eight
patients, 45 to 59 years of age, received unilateral
stereotaxic autografts of stellate ganglion, cut into
small fragments. No L-DOPA was administered
starting one week before transplantation and during
the entire follow-up period of 2 to 12 months.
Gradual improvements in bradykinesia and gait
disturbance were reported in seven of the eight
patients. From timed tests of motor function, the
improvement appeared to be bilateral. There was a
transient worsening of tremor in seven of the eight
patients from two to four weeks after
transplantation. Other complications of the surgery
included probable manifestations of stellate
ganglion removal. In one severely affected patient,
who did not improve, it was noted that the
catecholaminergic cells in the stellate gangion were
damaged.
A model presented by Sharp and coworkers
/127/ approaches the traditional "replacement"
model of neural tissue transplantation from a quite
different perspective. Lesions of the frontal cortex
induced atrophy of ventroposteromedial thalamic
neurons. Within 5 hours of cortical lesions, whisker
simulation was no longer able to activate thalamic
neurons. Nonetheless, at this time the thalamic
neurons were still intact, and cortical tetrodotoxin
did not eliminate the ability of whisker stimulation
to activate these thalamic neurons. These data
suggest that cortical inputs to the thalamus are not
directly required for whisker activation of thalamic
neurons; but, following cortical removal, the
synaptic connections from brainstem to thalamus
lose their efficacy. The neuronal death that occurs
following cortical removal is associated with
thalamie hypometabolism as measured by local
cerebral glucose utilization. Transplantation of fetal
cerebral cortex into the sites of cortical lesions
maintained thalamic glucose utilization and, in
some animals, restored the ability of whisker
stimulation to activate ventroposteromedial
thalamus. It is suggested that the cerebral cortex
provides a factor which is required for the survival
of neurons in the ventroposteromedial thalamus
and for the maintenance of synaptie connections
from the brainstem to the thalamus. Cortical
transplants may provide this trophie factor, thereby
facilitating the maintenance of these brain-
stem-ventroposteromedial thalamus synaptie
connections.
Another model of transplantation in cortical
injury, described by Bermudez-Rattoni et al. /9/
examined the effects of insular cortical lesions on
conditioned taste aversion. Lesions of the insular
cortex impaired conditioned taste aversion
learning, and transplantation of insular cortex into
the lesion site produced significant recovery of
taste aversion learning in insular cortex-lesioned
rats. Transplantation of occipital cortex did not
produce recovery. It was found that the insular
cortex grafts, but not the control occipital cortex
grafts, released acetyleholine in response to
depolarization, suggesting a role of aeetyleholine
release in the behavioral recovery. Afferents from
the cortical grafts were found to extend into the
host thalamus and amygdala, with these
connections developing over a 60-day time course,
roughly parallelling the time course of behavioral
recovery. Based on the hypothesized role of
acetylcholine in the behavioral recovery, effects of
NGF were examined. NGF was found to accelerate
the time-course of behavioral recovery after insular
cortex grafts, but had no effect on the long-term
outcome. NGF had no effect alone or when
combined with occipital cortex grafts. One
interesting aspect of these experiments/9/is that
they suggest a specific neuroehemical mediation
(i.e., acetylcholine) of a behavioral response to
cortical tissue transplantation.
A novel transplantation model described by
Sortwell and Sagen /133/ involved the use of
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"learned helplessness" and "forced swimming"
models of depression. "Learned helplessness"
describes a paradigm in which animals subjected to
inescapable stress show deficits in their ability to
avoid subsequent escapable stress. This deficit can
be alleviated by antidepressant drugs. Sortwell and
Sagen /133/ found that grafts of either adrenal
medulla (to produce catecholamines) or pineal
gland (to release serotonin), or a combination of
adrenal medulla and pineal gland grafts in the
frontal cortex prevented the learned helplessness
reponse, but control grafts of muscle tissue had no
effect. The "forced swimming" test involves the
measurement of immobility induced by forced
swimming in a confined enclosure, and is also used
as an animal model of depression. Transplantation
of adrenal medulla or pineal gland grafts, but not
control grafts of sciatic nerve, were found to reduce
immobility scores six to eight weeks after
transplantation. Biochemical and immunohisto-
chemical studies suggested that both the adrenal
medulla and pineal gland grafts survived well. This
is a new model which may suggest applications of
neural tissue grafting in cortically-mediated
phenomena.
Senatorov and associates /126/ suggest that
functional graft-host connections may be present
which cannot be activated under normal conditions.
Among other receptor systems, excitatory synapses
in the cerebral cortex may be mediated by the N-
methyl-D-aspartate (NMDA) receptor complex,
and activation of this receptor is regulated by
magnesium ions. When magnesium ion
concentrations are increased, greater levels of
glutamate occupancy are required for ionic
conductance by the channel. To determine whether
graft-host connections are present which are
"silent" under conditions of normal magnesium ion
concentration, cerebral cortex grafts were studied
using a slice preparation. Slices containing fetal
cortical grafts were examined in lesion cavities and
surrounding host cortex. In a medium of standard
artificial cerebrospinal fluid (CSF), electrical
stimulation of the host brain elicited field potentials
in four of seventeen preparations. When the
medium was changed to magnesium-free artificial
CSF, field potentials were recorded in 10 of the 17
rats. The amplitude and duration of the evoked
field potentials were increased in magnesium-free
medium, for both graft responses to host
stimulation and vice versa. NMDA antagonists
decreased the amplitude of the evoked field
potentials. These data suggest that connections
between transplanted cerebral cortex and adjacent
host brain may be mediated by NMDA-type
glutamatergic synapses. There is also a possibility
that some of these synapses are inactive under
normal conditions of endogenous synaptie
activation. These data would be consistent with
several findings that functional effects of grafts can
be enhanced by pharmacological stimulation; for
example, when SN grafts are activated by
amphetamine administration in animals with SN
lesions (cf. /40/), or when nicotonergie drugs are
employed to activate adrenal medulla grafts in pain
models (cf./118/).
Transplantation was employed in a model of
Down’s syndrome, using the trisomy 16 mouse.
These trisomy 16 animals do not survive past late
gestation, but fetal brain tissue from these animals
can survive as transplants in the brains of normal
mice. Hohmann and co-workers/63/reported that
these grafts did not show obvious abnormalities,
other than a transient increase in the expression of
amyloid precursor protein in trisomy 16 grafts as
compared to controls, which was seen two weeks
after transplantation but had disappeared by one
month. Hohmann /63/ also observed abnormal
amyloid precursor protein immunoreactivity in the
CA3 region of the host hippoeampus in many of
the animals bearing trisomy 16 grafts. Stoll et al.
/137/ also failed to find obvious signs of
Alzheimer’s-like degeneration in trisomy 16 grafts.
On the other hand, Holtzman and colleagues/64/
observed time-dependent atrophy of eholinergie
neurons within trisomy 16 grafts, using cell
suspension grafts into the hippocampus. This
atrophy was not a gross or obvious neuronal loss or
degeneration, but was manifest as a modest but
statistically significant decrease in the size of cell
somata (126 t2 versus 156 t2 for the controls). The
small size of the change suggests that it would not
be seen unless quantitative meaurements of cell
soma size were used. NGF administration was
found to reverse this cholinergic neuronal atrophy,
in that it increased the size of all cholinergie cell
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somata. The effects of NGF were not specific for
trisomy 16 grafts, however, in that the size of all
cholinergic neurons was increased. These papers
are further described in the accompanying report by
Geller/47/.
An example of the use of transplantation to
study physiological regulatory mechanisms was
presented by Murphy et al./96/. These experiments
involved the use of normal Wistar rats and a
spontaneously hypertensive rat strain to study
blood-pressure regulation. Transplantation of the
antero-ventral third ventricle region of the
hypothalamus, an area which has been implicated
in control of blood pressure, from hypertensive to
normal rats resulted in chronic blood pressure
elevations in normal Wistar rats. The ability of
tissue grafts to elevate blood pressure appeared to
depend strongly upon donor tissue age.
Hypothalamic tissue from E19-20 donors elevated
blood pressure for 30 60 days, while tissue from
younger E15-16 donors elevated blood pressure for
at least five months. When the younger E15-16
donors were used, even grafts of cerebral cortex
were able to induce blood pressure increases for at
least four months after transplantation. These data
suggest that the genetic control of blood pressure is
anatomically localized, does not involve complex
circuits, and that the abnormality may be
"transmissable" by transplantation of relatively
isolated tissue fragments. As the effect can be
transferred by even cortical tissue, the defect may
even be a general property of CNS from the
abnormal rat strain, rather than a hypothalamic
abnormality. This is an example of the use of
transplantation to localize primary versus
secondary control of neuronal circuit functions
/96/.
Studies by several groups have shown that
transplantation of the suprachiasmatic nucleus into
the hypothalamus of rats with suprachiasmatic
nucleus lesions, and consequently disrupted
circadian rhythms, can restore circadian
rhythmicity. Lehmann et al. /80/ described their
experiments on this topic. It was noted that the
restoration of circadian rhythmicity displays the
pacemaker properties of the donor cells,
demonstrating that the donor cells themselves
continue to express their intrinsic pacemaker
activity in the host brain. Another experiment
related to functions of the suprachiasraatic nucleus
was described by Aravich et al. /3/. Animals that
are given voluntary access to running wheels, but
are placed on a time-restricted feedittg schedule,
develop a disorder termed "activity-based
anorexia", which involves a progressive increase in
running and a substantial loss of weight as
compared to rats that are placed on a restricted
feeding schedule only. This syndrome is
aggravated by lesions of the suprachaismatie
nucleus or continuous illumination. Immediately
after receiving lesions of the suprachiasmatic
nucleus, animals received transplants of rostral
hypothalamus (containing the suprachiasmatic
nucleus) or control grafts of fetal cerebral cortex.
After 30 days, the animals were subjected to
conditions designed to induce activity-based
anorexia; namely, 1.5 h per day access to food and
22.5 h per day access to a running wheel.
Susceptibility to activity-based anorexia, defined as
a 25% weight loss, was seen in 69% of the controls
but in only 31% of the animals with hypothalamic
transplants. The animals with the hypothalamic
transplants showed a significantly greater food
intake than the animals with control grafts of
cerebral cortex, and no significant difference in
amount of running activity (whoel turns). The
animals with hypothalamic transplants, however,
tended to run more (not less, as might be expected)
than the controls. This is an interesting example of
the use of transplantation to examine the neural
circuits involved in a model of a neuropsychiatric
disorder.
An interesting technique for graft implantation
into spinal cord, which might be used in a modified
form in other anatomical regions such as cerebral
cortex, was described by Grijalva and colleagues
/53/. These investigators sought to improve graft-
host adhesion by enzymatic manipulation of the
site of a spinal cord lesion. Rats received spinal
cord lesions by the weight-drop method, and after
nine days received fetal spinal cord grafts
following aspiration of necrotic tissue at the lesion
site. In the experimental group, the lesion site was
bathed in a solution of 0.25% collagenase and 0.1%
hyaluronidase for 20 min, followed by application
of 0.1 M EDTA for 30 seconds. The enzymatic
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treatment did not change the total number of
animals with surviving grafts, or the total amount
of surviving graft tissue. There was, however,
approximately a 2.7-fold greater surface of graft-
host contact in the animals treated with enzyme
solution. In addition to spinal cord, similar methods
might be useful in other circumstances where graft-
host contact is impaired by scar formation.
Weiss /114,115,152/ presented data on a
method to generate cells from the CNS which
express neuronal and glial properties by relatively
simple manipulations in tissue culture. Cells
obtained from the brain under certain conditions
can be induced to proliferate in tissue culture under
the stimulating influence of epidermal growth
factor (EGF), generating groups of cells which they
have termed "neurospheres". These neurospheres
can be propagated and will continue to divide;
however, when they are subsequently grown on
coated surfaces without EGF, cells from these
neurospheres differentiate to form cells with both
neuronal and glial properties. It might eventually
be possible to use methods such as these to
generate, from the human CNS, glia, neurons, or
partially differentiated cells with sufficient neuron-
like properties to be useful for transplantation.
AIthongh most readily generated from fetal tissue,
,ara such cells can even be obtained from the
p(C)riveatricular striatum of mature animals. These
stadi(C)s suggest that stem cells representing
neural/glial progenitor cells continue to be present
even in the mature CNS to some extent. Under
appropriate conditions, it may be that these cells
can be induced to differentiate to form mature
neurons or glia.
Possibly the most exciting new development
was presented by Sagen and associates/117,119/,
who discussed the possible use of adrenal medulla
transplants for chronic pain. Sagen first reviewed
their findings on the effects of adrenal medulla
transplants in animal models of pain, including data
showing that these grafts are effective in alleviating
manifestations of pain, such as vocalizations and
weight loss, in chronic pain models/54,120,149/.
Adrenal medulla grafts were tried in terminal
cancer patients with severe pain who had a
prognosis of six months of less. Each patient
received an allograft of 1.5 precultured adrenal
medulla into the spinal cord by lumbar cisternal
puncture, and immunosuppression by cyclosporin
for approximately two weeks. Three patients aged
52-69 years, with carcinoma of the colon and
suffering from severe pain, showed substantial
improvement, consisting of a lowering of self-
assessed pain scores. All three became nearly pain-
free between 3 and 16 weeks after the surgery.
Each of the three carcinoma patients remained
pain-free therafter, and in two cases lived for 11 to
12 months free of pain. Of the other two patients in
the trial, aged 41 and 49 years, with breast
carcinoma and Gardiner’s syndrome, one reported
no pain relief, and only transient improvement was
observed for the fifth patient. These data suggest
that adrenal medulla transplantation may
eventually be found to be a significant alternative
or adjunct to narcotics for severe chronic pain
/117,119/.
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